Jinsong Liu, M.D., Ph.D., M.A.

Peer-Reviewed Articles

1. Brodsky AL, Asare A, Fellman B, Anderson K, Yao J, Lee S, Tran H, Xu X, Liu J, Celestino J, Hajek RA, Morgan MB, Mohammad M, Soliman P, Shafer A, Sood AK, Bodurka D, Fleming ND, Onstad Grinsfelder M, Milojevic L, Jazaeri AA, Mills GB, Coleman RL, Westin SN. Combination Therapy with Copanlisib and Niraparib in Patients with Recurrent Endometrial and Ovarian Cancer (COPANIRA): Efficacy, Toxicity, and Translational Insights. Clin Cancer Res, 2026. e-Pub 2026. PMID: 41528970.
2. Bayraktar E, Rodriguez-Aguayo C, Sudhir Kumar ES∙, Mangala LS, Jennings NB, Bayram NN, Corvigno S, Asare A, Ivan C, Kim MS, Vu TC, Hanjra P, Kim S, Ahumada AL, Wu W, Lee S, Szymanowska A, Oztatlici H, Estecio MR, Lee J, Jain AK, Sahni N, Hagan JP, Baylin S, Liu J, Lopez-Berestein G, Pradeep S, Sood AK. Epigenetic modulation of BARD1 to enhance anti-VEGF therapy. Cell Rep Med 6(9), 2025. e-Pub 2025. PMID: 40907495.
3. Dai Y, Knisely A, Yano M, Dang M, Hinchcliff EM, Lee S, Welp A, Chelvanambi M, Lastrapes M, Liu H, Yuan Z, Wang C, Nie H, Jean S, Montaner LJ, Hou J, Patel A, Patel S, Fellman B, Yuan Y, Sun B, Pandurengan RK, Parra Cuentas ER, Celestino J, Liu Y, Liu J, Hillman R, Westin SN, Sood AK, Soliman PT, Shafer A, Meyer LA, Gershenson DM, Vining D, Ganeshan D, Lu K, Wargo JA, Peng W, Zhang R, Wang L, Jazaeri AA. PPP2R1A mutations portend improved survival after cancer immunotherapy. Nature 644(8076):537-546, 2025. e-Pub 2025. PMID: 40604275.
4. Chen M, Yamaguchi H, Gao Y, Xia W, Chang JT, Hsiao Y, Shegute TW, Lin Z, Wu C, Wang Y, Litton JK, Ding Q, Wei Y, Chu Y, Meric-Bernstam F, Piwnica-Worms H, Arun B, Ahnert JR, Liu J, Yao J, Chang W, Wang H, Tapia C, Albarracin CT, Keyomarsi K, Wang S, Wang Y, Hortobagyi GN, Lin C, Yang L, Yu D, Hung M. FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer models. J Clin Invest 135(14), 2025. e-Pub 2025. PMID: 40460005.
5. Chelariu-Raicu A, Vu TC, Umamaheswaran S, Stur E, Hanjra P, Han Y, Hu M, Lin J, Lawson BC, Liu J, Sood AK, Wen Y. IMGN853 Induces Autophagic Cell Death in Combination Therapy for Ovarian Cancer. Cancer Res Commun 5(4):512-526, 2025. e-Pub 2025. PMID: 40029935.
6. Zheng, L, Tabet, GC, Guo, CC, Rizvi, YQ, Raso, G, Liu, J, Ding, Q, Baraban, EG, Zhao, J. Clinicopathological study of 34 cases of clear cell adenocarcinoma of the urinary tract and diagnostic value of SOX 17 in its differential diagnosis. Human Pathology 157, 2025. e-Pub 2025. PMID: 40189026.
7. How JA, Dang M, Lee S, Fellman B, Westin SN, Sood AK, Fleming ND, Shafer A, Yuan Y, Liu J, Zhao L, Celestino J, Hajek R, Morgan MB, Parra ER, Laberiano Fernandez CD, Arrechedera CA, Solis Soto LM, Schmeler KM, Nick A, Lu KH, Coleman R, Wang L, Jazaeri AA. Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial. Med 6(1), 2025. e-Pub 2025. PMID: 39151421.
8. Wilke RN, Liu J, Westin SN, Fellman BM, Sims TT, Pham M, Rangel K, Sey E, Rauh-Hain JA, Lu KH, Sood AK, Fleming ND. The association of chemotherapy response score and homologous recombination deficiency in patients undergoing interval tumor reductive surgery following neoadjuvant chemotherapy. Int J Gynecol Cancer, 2025. PMID: 39414313.
9. Sutton MN, Glazer SE, Zaki AA, Napoli A, Yang P, Bhosale P, Liu J, Gammon ST, Piwnica-Worms D. Statins inhibit onco-dimerization of the 4Ig isoform of B7-H3. bioRxiv, 2024. PMID: 39763965.
10. Awasthi, S, Dobrolecki, LE, Sallas, C, Zhang, X, Li, Y, Khazaei, S, Ghosh, S, Jeter, CR, Liu, J, Mills, GB, Westin, SN, Lewis, MT, Peng, W, Sood, AK, Yap, TA, Yi, SS, McGrail, DJ, Sahni, N. UBA1 inhibition sensitizes cancer cells to PARP inhibitors. Cell Reports Medicine 5(12), 2024. e-Pub 2024. PMID: 39626673.
11. Reihanisaransari, R, Gajjela, CC, Wu, X, Ishrak, R, Corvigno, S, Zhong, Y, Liu, J, Sood, AK, Mayerich, D, Berisha, S, Reddy, RK. Rapid Hyperspectral Photothermal Mid-Infrared Spectroscopic Imaging from Sparse Data for Gynecologic Cancer Tissue Subtyping. Analytical Chemistry 96(40):15880-15887, 2024. e-Pub 2024. PMID: 39312212.
12. Santiago-O'Farrill JM, Blessing Bollu A, Yang H, Orellana V, Pina M, Zhang X, Liu J, Bast RC, Lu Z. Crizotinib enhances PARP inhibitor efficacy in ovarian cancer cells and xenograft models by inducing autophagy. Mol Cancer Res 22(9):840-851, 2024. e-Pub 2024. PMID: 38780897.
13. Han CY, Lu KH, Corrigan G, Perez A, Kohring SD, Celestino J, Bedi D, Bedia E, Bevers T, Boruta D, Carlson M, Holman L, Leeds L, Mathews C, McCann G, Moore RG, Schlumbrecht M, Slomovitz B, Tobias D, Williams-Brown Y, Bevers MW, Liu J, Gornet TG, Handy BC, Lu Z, Bedia JS, Skates SJ, Bast RC. Normal Risk Ovarian Screening Study: 21-Year Update. J Clin Oncol 42(10):1102-1109, 2024. e-Pub 2024. PMID: 38194613.
14. Vo D, Liu Y, Sood AK, Rezvani K, Jazaeri AA, Liu J. EGFR, HLA-G, CD70, c-MET, and NY-ESO1 as Potential Biomarkers in High Grade Epithelial Ovarian Carcinoma. Cancer Biomark 39(4):289-298, 2024. e-Pub 2024. PMID: 38250760.
15. Li, Y, Dobrolecki, LE, Sallas, C, Zhang, X, Kerr, TD, Bisht, D, Wang, Y, Awasthi, S, Kaundal, B, Wu, S, Peng, W, Mendillo, ML, Lu, Y, Jeter, CR, Peng, G, Liu, J, Westin, SN, Sood, AK, Lewis, MT, Das, J, Yi, S, Bedford, MT, McGrail, DJ, Sahni, N. PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition. Cell Reports Medicine 4(12), 2023. e-Pub 2023. PMID: 38118413.
16. Corvigno S, Badal S, Spradlin ML, Keating M, Pereira I, Stur E, Bayraktar, E, Foster KI, Bateman NW, Barakat W, Darcy KM, Conrads TP, Maxwell GL, Lorenzi PL, Lutgendorf SK, Wen YF, Zhao L, Thaker PH, Goodheart MJ, Liu J, Fleming N, Lee SH, Eberlin LS, and Sood AK. In situ profiling reveals metabolic alterations in the tumor microenvironment of ovarian cancer after chemotherapy. NPJ Precis Oncol 7(1):115, 2023. e-Pub 2023. PMID: 37923835.
17. Zhang, X, Yao, J, Li, X, Niu, N, Liu, Y, Hajek, RA, Peng, G, Westin, SN, Sood, AK, Liu, J. Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer (News highlight from MD Anderson Cancer Center). Sci Adv 9(29), 2023. e-Pub 2023. PMID: 37478190.
18. Gajjela CC, Brun M, Mankar R, Corvigno S, Kennedy N, Zhong Y, Liu J, Sood AK, Mayerich D, Berisha S, Reddy R. Leveraging mid-infrared spectroscopic imaging and deep learning for tissue subtype classification in ovarian cancer. (MD Anderson News Highlight). Analyst 148(12):2699-2708, 2023. e-Pub 2023. PMID: 37218522.
19. LaFargue CJ, Amero P, Noh K, Mangala LS, Wen Y, Bayraktar E, Umamaheswaran S, Stur E, Dasari SK, Ivan C, Pradeep S, Yoo W, Lu C, Jennings NB, Vathipadiekal V, Hu W, Chelariu-Raicu A, Ku Z, Deng H, Xiong W, Choi HJ, Hu M, Kiyama T, Mao CA, Ali-Fehmi R, Birrer MJ, Liu J, Zhang N, Lopez-Berestein G, de Franciscis V, An Z, Sood AK. Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L. Nat Commun 14(1):2407, 2023. e-Pub 2023. PMID: 37100807.
20. Zhang X, Yao J, Niu N, Li X, Liu Y, Huo L, Euscher ED, Wang H, Bell D, Sood AK, Wang G, Lawson BC, Ramalingam P, Malpica A, Sahin AA, Ding Q, Liu J. SOX17: A Highly Sensitive and Specific Immunomarker for Ovarian and Endometrial Carcinomas. (News highlight from MD Anderson Cancer Center). Mod Pathol 36(2):100001, 2023. e-Pub 2023. PMID: 36853778.
21. Li X, Zhong Y, Zhang X, Sood AK, Liu J. Spatiotemporal view of malignant histogenesis and macroevolution via formation of polyploid giant cancer cells. (News highlight from MD Anderson Cancer Center). Oncogene 42(9):665-678, 2023. e-Pub 2023. PMID: 36596845.
22. Handley KF, Sims TT, Bateman NW, Glassman D, Foster KI, Lee S, Yao J, Yao H, Fellman BM, Liu J, Lu Z, Conrads KA, Hood BL, Barakat W, Zhao L, Zhang J, Westin SN, Celestino J, Rangel KM, Badal S, Pereira I, Ram PT, Maxwell GL, Eberlin LS, Futreal PA, Bast RC, Fleming ND, Conrads TP, Sood AK. Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics. JAMA Netw Open 5(10):e2236626, 2022. e-Pub 2022. PMID: 36239936.
23. Chu, YY, Chen, MK, Wei, Y, Lee, H, Xia, W, Wang, Y, Yam, C, Hsu, JL, Wang, HL, Chang, W, Yamaguchi, H, Jiang, Z, Liu, C, Li, CF, Nie, L, Chan, LC, Gao, Y, Wang, SC, Liu, J, Westin, SN, Lee, S, Sood, AK, Yang, L, Hortobagyi, GN, Yu, D, Hung, MC. Targeting the ALK–CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. Nature Cancer 3(10):1211-1227, 2022. e-Pub 2022. PMID: 36253486.
24. Stur, E, Bayraktar, E, Dal Molin, GZ, Wu, S, Mangala, LS, Yao, H, Wang, Y, Ram, P, Corvigno, S, Chen, H, Liang, H, Tworoger, SS, Levine, DA, Lutgendorf, SK, Liu, J, Moore, KM, Baggerly, KA, Karlan, BY, Sood, AK. Molecular Analysis of Short- versus Long-Term Survivors of High-Grade Serous Ovarian Carcinoma. Cancers 14(17), 2022. e-Pub 2022. PMID: 36077735.
25. Wen Y, Chelariu-Raicu A, Umamaheswaran S, Nick AM, Stur E, Hanjra P, Jiang D, Jennings NB, Chen X, Corvigno S, Glassman D, Lopez-Berestein G, Liu J, Hung MC, Sood AK. Endothelial p130cas confers resistance to anti-angiogenesis therapy. Cell Rep 39(12):110999, 2022. e-Pub 2022. PMID: 35732127.
26. Cho MS, Lee H, Gonzalez-Delgado R, Li D, Sasano T, Carlos-Alcalde W, Ma Q, Liu J, Sood AK, Afshar-Kharghan V. Platelets Increase the Expression of PD-L1 in Ovarian Cancer. Cancers (Basel) 14(10), 2022. e-Pub 2022. PMID: 35626102.
27. Silva EG, Lawson BC, Ramalingam P, Liu J, Shehabeldin A, Marques-Piubelli ML, Malpica A. Precursors in the ovarian stroma: another pathway to explain the origin of ovarian serous neoplasms. Hum Pathol 127:136-145, 2022. e-Pub 2022. PMID: 35427637.
28. Stur E, Corvigno S, Xu M, Chen K, Tan Y, Lee S, Liu J, Ricco E, Kraushaar D, Castro P, Zhang J, Sood AK. Spatially resolved transcriptomics of high-grade serous ovarian carcinoma. iScience 25(3):103923, 2022. e-Pub 2022. PMID: 35252817.
29. Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim TB, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer LA, Sun CC, Sood AK, Coleman RL, Mills GB. Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res 27(23):6354-6365, 2021. e-Pub 2021. PMID: 34518313.
30. Niu N, Yao J, Bast RC, Sood AK, Liu J. IL-6 promotes drug resistance through formation of polyploid giant cancer cells and stromal fibroblast reprogramming. Oncogenesis 10(9):65, 2021. e-Pub 2021. PMID: 34588424.
31. Corvigno S, Burks JK, Hu W, Zhong Y, Jennings NB, Fleming ND, Westin SN, Fellman B, Liu J, Sood AK. Immune microenvironment composition in high-grade serous ovarian cancersbased on BRCA mutational status. J Cancer Res Clin Oncol 147(12):3545-3555, 2021. e-Pub 2021. PMID: 34476576.
32. Shen X, Fang K, Ru Yie KH, Zhou Z, Shen Y, Wu S, Zhu Y, Deng Z, Ma P, Ma J, Liu J. High proportion strontium-doped micro-arc oxidation coatings enhance early osseointegration of titanium in osteoporosis by anti-oxidative stress pathway. Bioact Mater 10:405-419, 2021. e-Pub 2021. PMID: 34901556.
33. Katayama H, Kobayashi M, Irajizad E, Sevillarno A, Patel N, Mao X, Rusling L, Vykoukal J, Cai Y, Hsiao F, Yu CY, Long J, Liu J, Esteva F, Fahrmann J, Hanash S. Protein citrullination as a source of cancer neoantigens. J Immunother Cancer 9(6), 2021. e-Pub 2021. PMID: 34112737.
34. Lei G, Zhang Y, Hong T, Zhang X, Liu X, Mao C, Yan Y, Koppula P, Cheng W, Sood AK, Liu J, Gan B. Ferroptosis as a mechanism to mediate p53 function in tumor radiosensitivity. Oncogene 40(20):3533-3547, 2021. e-Pub 2021. PMID: 33927351.
35. Niu N, Shen W, Zhong Y, Bast RC, Jazaeri A, Sood AK, Liu J. Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas. Hum Pathol 113:20-27, 2021. e-Pub 2021. PMID: 33887301.
36. Ma S, McGuire MH, Mangala LS, Lee S, Stur E, Hu W, Bayraktar E, Villar-Prados A, Ivan C, Wu SY, Yokoi A, Dasari SK, Jennings NB, Liu J, Lopez-Berestein G, Ram P, Sood AK. Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype. Cell Rep 34(6):108726, 2021. e-Pub 2021. PMID: 33567287.
37. Zhong Y, Liu J, Li X, Westin SN, Malpica A, Lawson BC, Lee S, Fellman BM, Coleman RL, Sood AK, Fleming ND. A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy. Cancers (Basel) 13(4):1-14, 2021. e-Pub 2021. PMID: 33572451.
38. Ai D, Yao J, Yang F, Huo L, Chen H, Lu W, Soto LMS, Jiang M, Raso MG, Wang S, Bell D, Liu J, Wang H, Tan D, Torres-Cabala C, Gan Q, Wu Y, Albarracin C, Hung MC, Meric-Bernstam F, Wistuba II, Prieto VG, Sahin AA, Ding Q. TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Mod Pathol 34(4):710-719, 2020. e-Pub 2020. PMID: 33011748.
39. Wen Y, Wang Y, Chelariu-Raicu A, Stur E, Liu Y, Corvigno S, Bartsch F, Redfern L, Zand B, Kang Y, Liu J, Baggerly K, Sood AK. Blockade of the Short Form of Prolactin Receptor Induces FOXO3a/EIF-4EBP1-Mediated Cell Death in Uterine Cancer. Mol Cancer Ther 19(9):1943-1954, 2020. e-Pub 2020. PMID: 32737156.
40. Lee S, Zhao L, Rojas C, Bateman NW, Yao H, Lara OD, Celestino J, Morgan MB, Nguyen TV, Conrads KA, Rangel KM, Dood RL, Hajek RA, Fawcett GL, Chu RA, Wilson K, Loffredo JL, Viollet C, Jazaeri AA, Dalgard CL, Mao X, Song X, Zhou M, Hood BL, Banskota N, Wilkerson MD, Te J, Soltis AR, Roman K, Dunn A, Cordover D, Eterovic AK, Liu J, Burks JK, Baggerly KA, Fleming ND, Lu KH, Westin SN, Coleman RL, Mills GB, Casablanca Y, Zhang J, Conrads TP, Maxwell GL, Futreal PA, Sood AK. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Rep 31(2):107502, 2020. e-Pub 2020. PMID: 32294438.
41. Salem A, Pinto K, Koch M, Liu J, Silva EG. Are polyploid giant cancer cells in high grade serous carcinoma of the ovary blastomere-like cancer stem cells?. Ann Diagn Pathol 46:151505, 2020. e-Pub 2020. PMID: 32387856.
42. Xiong C, Wen Y, Zhao J, Yin D, Xu L, Chelariu-Raicu A, Yao C, Leng X, Liu J, Chaudhari RR, Zhang S, Sood AK, Li C. Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions. Sci Rep 10(1):520, 2020. e-Pub 2020. PMID: 31949258.
43. Lara OD, Krishnan S, Wang Z, Corvigno S, Zhong Y, Lyons Y, Dood R, Hu W, Qi L, Liu J, Coleman RL, Westin SN, Fleming ND, Cristini V, Rao A, Burks J, Sood AK. Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. Sci Rep 9(1):17589, 2019. e-Pub 2019. PMID: 31772388.
44. Yokoi A, Villar-Prados A, Oliphint PA, Zhang J, Song X, De Hoff P, Morey R, Liu J, Roszik J, Clise-Dwyer K, Burks JK, O'Halloran TJ, Laurent LC, Sood AK. Mechanisms of nuclear content loading to exosomes. Sci Adv 5(11):eaax8849, 2019. e-Pub 2019. PMID: 31799396.
45. Lawson BC, Euscher ED, Bassett RL, Liu J, Ramalingam P, Zhong Y, Fleming ND, Malpica A. A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma: Is it Clinically Relevant?. Am J Surg Pathol 44(2):206-213, 2019. e-Pub 2019. PMID: 31651523.
46. Yang T, Zhou R, Yu S, Yu S, Cui Z, Hu P, Liu J, Qiao Q, Zhang J. Cytoplasmic SIRT1 inhibits cell migration and invasion by impeding epithelial-mesenchymal transition in ovarian carcinoma. Mol Cell Biochem 459(1-2):157-169, 2019. e-Pub 2019. PMID: 31317367.
47. Fang Y, McGrail DJ, Sun C, Labrie M, Chen X, Zhang D, Ju Z, Vellano CP, Lu Y, Li Y, Jeong KJ, Ding Z, Liang J, Wang SW, Dai H, Lee S, Sahni N, Mercado-Uribe I, Kim TB, Chen K, Lin SY, Peng G, Westin SN, Liu J, O'Connor MJ, Yap TA, Mills GB. Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. Cancer Cell 35(6):851-867.e7, 2019. e-Pub 2019. PMID: 31185210.
48. Srivastava AK, Banerjee A, Cui T, Han C, Cai S, Liu L, Wu D, Cui R, Li Z, Zhang X, Xie G, Selvendiran K, Patnaik S, Karpf AR, Liu J, Cohn DE, Wang QE. Inhibition of miR-328-3p Impairs Cancer Stem Cell Function and Prevents Metastasis in Ovarian Cancer. Cancer Res 79(9):2314-2326, 2019. e-Pub 2019. PMID: 30894370.
49. Sans M, Zhang J, Lin JQ, Feider CL, Giese N, Breen MT, Sebastian K, Liu J, Sood AK, Eberlin LS. Performance of the MasSpec Pen for Rapid Diagnosis of Ovarian Cancer. Clin Chem 65(5):674-683, 2019. e-Pub 2019. PMID: 30770374.
50. Radhakrishnan R, Ha JH, Jayaraman M, Liu J, Moxley KM, Isidoro C, Sood AK, Song YS, Dhanasekaran DN. Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts. Cancer Lett 442:464-474, 2019. e-Pub 2019. PMID: 30503552.
51. Shen W, Niu N, Lawson B, Qi L, Zhang J, Li T, Zhang H, Liu J. GATA6: a new predictor for prognosis in ovarian cancer. Hum Pathol 86:163-169, 2019. e-Pub 2019. PMID: 30633927.
52. Dood RL, Fleming ND, Coleman RL, Westin SN, Lara OD, LaFargue CJ, Liu J, Sood AK. When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System. Int J Gynecol Cancer 28(8):1485-1490, 2018. e-Pub 2018. PMID: 30036226.
53. Gharpure KM, Pradeep S, Sans M, Rupaimoole R, Ivan C, Wu SY, Bayraktar E, Nagaraja AS, Mangala LS, Zhang X, Haemmerle M, Hu W, Rodriguez-Aguayo C, McGuire M, Mak CSL, Chen X, Tran MA, Villar-Prados A, Pena GA, Kondetimmanahalli R, Nini R, Koppula P, Ram P, Liu J, Lopez-Berestein G, Baggerly K, S Eberlin L, Sood AK. FABP4 as a key determinant of metastatic potential of ovarian cancer. Nat Commun 9(1):2923, 2018. e-Pub 2018. PMID: 30050129.
54. Shen J, Ju Z, Zhao W, Wang L, Peng Y, Ge Z, Nagel ZD, Zou J, Wang C, Kapoor P, Ma X, Ma D, Liang J, Song S, Liu J, Samson LD, Ajani JA, Li GM, Liang H, Shen X, Mills GB, Peng G. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med 24(5):556-562, 2018. e-Pub 2018. PMID: 29736026.
55. Sutton MN, Yang H, Huang GY, Fu C, Pontikos M, Wang Y, Mao W, Pang L, Yang M, Liu J, Parker-Thornburg J, Lu Z, Bast RC. RAS-related GTPases DIRAS1 and DIRAS2 induce autophagic cancer cell death and are required for autophagy in murine ovarian cancer cells. Autophagy 14(4):637-653, 2018. e-Pub 2018. PMID: 29368982.
56. Wan L, Xu K, Wei Y, Zhang J, Han T, Fry C, Zhang Z, Wang YV, Huang L, Yuan M, Xia W, Chang WC, Huang WC, Liu CL, Chang YC, Liu J, Wu Y, Jin VX, Dai X, Guo J, Liu J, Jiang S, Li J, Asara JM, Brown M, Hung MC, Wei W. Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function. Mol Cell 69(2):279-291.e5, 2018. e-Pub 2018. PMID: 29351847.
57. Cao Y, Jiang Y, Lin X, Liu J, Lu T, Cheng W, Yan F. Dynamic Prediction of Outcome for Patients With Ovarian Cancer: Application of a Joint Model for Longitudinal Cancer Antigen 125 Values. Int J Gynecol Cancer 28(1):85-91, 2018. e-Pub 2018. PMID: 29135568.
58. Noh K, Mangala LS, Han HD, Zhang N, Pradeep S, Wu SY, Ma S, Mora E, Rupaimoole R, Jiang D, Wen Y, Shahzad MMK, Lyons Y, Cho M, Hu W, Nagaraja AS, Haemmerle M, Mak CSL, Chen X, Gharpure KM, Deng H, Xiong W, Kingsley CV, Liu J, Jennings N, Birrer MJ, Bouchard RR, Lopez-Berestein G, Coleman RL, An Z, Sood AK. Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Rep 21(10):2785-2795, 2017. e-Pub 2017. PMID: 29212026.
59. Hou D, Xu G, Zhang C, Li B, Qin J, Hao X, Liu Q, Zhang X, Liu J, Wei J, Gong Y, Liu Z, Shao C. Berberine induces oxidative DNA damage and impairs homologous recombination repair in ovarian cancer cells to confer increased sensitivity to PARP inhibition. Cell Death Dis 8(10):e3070, 2017. e-Pub 2017. PMID: 28981112.
60. Zhang J, Rector J, Lin JQ, Young JH, Sans M, Katta N, Giese N, Yu W, Nagi C, Suliburk J, Liu J, Bensussan A, DeHoog RJ, Garza KY, Ludolph B, Sorace AG, Syed A, Zahedivash A, Milner TE, Eberlin LS. Nondestructive tissue analysis for ex vivo and in vivo cancer diagnosis using a handheld mass spectrometry system. Sci Transl Med 9(406), 2017. e-Pub 2017. PMID: 28878011.
61. Lyons YA, Pradeep S, Wu SY, Haemmerie M, Hansen JM, Wagner MJ, Villar-Prados A, Nagaraja AS, Dood RL, Previs RA, Hu W, Zhao Y, Mak DH, Xiao Z, Melendez BD, Lizee GA, Mercado-Uribe I, Baggerly KA, Hwu P, Liu J, Overwijk WW, Coleman RL, Sood AK. Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcome adaptive resistance to anti-VEGF therapy. Oncotarget 8(57):96496-96505, 2017. e-Pub 2017. PMID: 29228548.
62. Niu N, Mercado-Uribe I, Liu J. Dedifferentiation into blastomere-like cancer stem cells via formation of polyploid giant cancer cells. Oncogene 36(34):4887-4900, 2017. e-Pub 2017. PMID: 28436947.
63. Haemmerle M, Taylor ML, Gutschner T, Pradeep S, Cho MS, Sheng J, Lyons YM, Nagaraja AS, Dood RL, Wen Y, Mangala LS, Hansen JM, Rupaimoole R, Gharpure KM, Rodriguez-Aguayo C, Yim SY, Lee JS, Ivan C, Hu W, Lopez-Berestein G, Wong ST, Karlan BY, Levine DA, Liu J, Afshar-Kharghan V, Sood AK. Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nat Commun 8(1):310, 2017. e-Pub 2017. PMID: 28827520.
64. Zhang M, Adeniran AJ, Vikram R, Tamboli P, Pettaway C, Bondaruk J, Liu J, Baggerly K, Czerniak B. Carcinoma of the Urethra. Hum Pathol 72:35-44, 2017. e-Pub 2017. PMID: 28827100.
65. Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight, 2017. e-Pub 2017. PMID: 28814667.
66. Sans M, Gharpure KM, Tibshirani R, Zhang J, Liang L, Liu J, Young JH, Dood R, Sood AK, Eberlin L. Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging. Cancer Res 77(11):2903-2913, 2017. e-Pub 2017. PMID: 28416487.
67. Zhou J, Alfraidi A, Zhang S, Santiago-O'Farrill JM, Yerramreddy Reddy VK, Alsaadi A, Ahmed AA, Yang H, Liu J, Mao W, Wang Y, Takemori H, Vankayalapati H, Lu Z, Bast RC. A novel compound ARN-3236 inhibits Salt Inducible Kinase 2 and sensitizes ovarian cancer cell lines and xenografts to paclitaxel. Clin Cancer Res 23(8):1945-1954, 2017. e-Pub 2017. PMID: 27678456.
68. Gorski JW, Taylor JS, Zhang J, Liu J, Jazaeri AA. Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole. Gynecol Oncol Rep 20:93-96, 2017. e-Pub 2017. PMID: 28393092.
69. Jiang Y, Yan F, Liang L, Wan Y, Liu J, Cheng W. Meta-analysis demonstrates no association between p16 (ink4a) promoter methylation and epithelial ovarian cancer. Arch Gynecol Obstet 295(3):697-704, 2016. e-Pub 2016. PMID: 28000027.
70. Niu N, Zhang J, Zhang N, Mercado-Uribe I, Tao F, Han ZB, Pathak S, Multani AS, Kuang J, Yao J, Bast RC, Sood AK, Hung MC, Liu J. Linking Genomic Reorganization to Tumor Initiation via the Giant Cell Cycle. Oncogenesis 5(12):e281, 2016. e-Pub 2016. PMID: 27991913.
71. Yang L, Achreja A, Yeung TL, Mangala LS, Jiang D, Han C, Baddour J, Marini JC, Ni J, Nakahara R, Wahlig S, Chiba L, Kim SH, Morse J, Pradeep S, Nagaraja AS, Haemmerle M, Kyunghee N, Derichsweiler M, Plackemeier T, Mercado-Uribe I, Lopez-Berestein G, Moss T, Ram PT, Liu J, Lu X, Mok SC, Sood AK, Nagrath D. Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth. Cell Metab 24(5):685-700, 2016. e-Pub 2016. PMID: 27829138.
72. Ha JH, Yan M, Gomathinayagam R, Jayaraman M, Husain S, Liu J, Mukherjee P, Reddy EP, Song YS, Dhanasekaran DN. Aberrant expression of JNK-associated leucine-zipper protein, JLP, promotes accelerated growth of ovarian cancer. Oncotarget 7(45):72845-72859, 2016. e-Pub 2016. PMID: 27655714.
73. Wang Y, Hu L, Ji P, Teng F, Tian W, Liu Y, Cogdell D, Liu J, Sood AK, Broaddus R, Xue F, Zhang W. MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis. J Hematol Oncol 9(1):112, 2016. e-Pub 2016. PMID: 27760566.
74. Xiao X, Yang G, Bai P, Gui S, Nyuyen TM, Mercado-Uribe I, Yang M, Zou J, Li Q, Xiao J, Chang B, Liu G, Wang H, Liu J. Inhibition of nuclear factor-kappa B enhances the tumor growth of ovarian cancer cell line derived from a low-grade papillary serous carcinoma in p53-independent pathway. BMC Cancer 16:582, 2016. e-Pub 2016. PMID: 27484466.
75. Liang L, Jiang Y, Chen JS, Niu N, Piao J, Ning J, Zu Y, Zhang J, Liu J. B7-H4 expression in ovarian serous carcinoma: a study of 306 cases. Hum Pathol 57(1-6), 2016. e-Pub 2016. PMID: 27349304.
76. Liang L, Olar A, Niu N, Jiang Y, Cheng W, Bian XW, Yang W, Zhang J, Yemelyanova A, Malpica A, Zhang Z, Fuller GN, Liu J. Primary Glial and Neuronal Tumors of the Ovary or Peritoneum: A Clinicopathologic Study of 11 Cases. Am J Surg Pathol 40(6):847-56, 2016. e-Pub 2016. PMID: 26990854.
77. Wang J, Hu K, Guo J, Cheng F, Lv J, Jiang W, Lu W, Liu J, Pang X, Liu M. Suppression of KRas mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK (Cover picture of issue). Nat Commun 7:11363, 2016. e-Pub 2016. PMID: 27193833.
78. Chaluvally-Raghavan P, Jeong KJ, Pradeep S, Silva AM, Yu S, Liu W, Moss T, Rodriguez-Aguayo C, Zhang D, Ram P, Liu J, Lu Y, Lopez-Berestein G, Calin GA, Sood AK, Mills GB. Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. Cell Rep 15(7):1493-1504, 2016. e-Pub 2016. PMID: 27160903.
79. Pan Y, Robertson G, Pedersen L, Lim E, Hernandez-Herrera A, Rowat AC, Patil SL, Chan CK, Wen Y, Zhang X, Basu-Roy U, Mansukhani A, Chu A, Sipahimalani P, Bowlby R, Brooks D, Thiessen N, Coarfa C, Ma Y, Moore RA, Schein JE, Mungall AJ, Liu J, Pecot CV, Sood AK, Jones SJ, Marra MA, Gunaratne PH. miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. Oncotarget, 2016. e-Pub 2016. PMID: 27036018.
80. Morgado M, Sutton MN, Simmons M, Warren CR, Lu Z, Constantinou PE, Liu J, Francis LL, Conlan RS, Bast RC, Carson DD. Tumor necrosis factor-α and interferon-γ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFκB. Oncotarget 7(12):14871-84, 2016. e-Pub 2016. PMID: 26918940.
81. Zhang S, Mercado-Uribe I, Sood A, Bast RC, Liu J. Coevolution of Neoplastic Epithelial Cells and Multilineage Stroma via Polyploid Giant Cells during Immortalization and Transformation of Mullerian Epithelial Cells (Cover Story). Genes Cancer 7(3-4):60-72, 2016. e-Pub 2016. PMID: 27382431.
82. Liang L, Zheng W, Liu J, Liang SX. Assessment of the Utility of PAX8 Immunohistochemical Stain in Diagnosing Endocervical Glandular Lesions. Arch Pathol Lab Med 140(2):148-52, 2016. e-Pub 2016. PMID: 26910219.
83. Zand B, Previs RA, Zacharias NM, Rupaimoole R, Mitamura T, Nagaraja AS, Guindani M, Dalton HJ, Yang L, Baddour J, Achreja A, Hu W, Pecot CV, Ivan C, Wu SY, McCullough CR, Gharpure KM, Shoshan E, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Wang Y, Nick AM, Davies MA, Armaiz-Pena G, Liu J, Lutgendorf SK, Baggerly KA, Eli MB, Lopez-Berestein G, Nagrath D, Bhattacharya PK, Sood AK. Role of Increased N-Acetylaspartate Levels in Cancer. J Natl Cancer Inst 108(6):djv426, 2016. e-Pub 2016. PMID: 26819345.
84. Yang H, Das P, Yu Y, Mao W, Wang Y, Baggerly K, Wang Y, Marquez RT, Bedi A, Liu J, Fishman D, Lu Z, Bast RC. NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanisms. Oncotarget 7(3):3018-32, 2016. e-Pub 2016. PMID: 26689988.
85. Liang L, Huang H, Dadhania V, Zhang J, Zhang M, Liu J. Renal cell carcinoma metastatic to the ovary or fallopian tube: a clinicopathological study of 9 cases. Hum Pathol 51:96-102, 2016. e-Pub 2016. PMID: 27067787.
86. Liang L, Zhang Y, Malpica A, Ramalingam P, Euscher ED, Fuller GN, Liu J. Gliomatosis peritonei: a clinicopathologic and immunohistochemical study of 21 cases. Mod Pathol 28(12):1613-1620, 2015. e-Pub 2015. PMID: 26564007.
87. Pradeep S, Huang J, Mora EM, Nick AM, Cho MS, Wu SY, Noh K, Pecot CV, Rupaimoole R, Stein MA, Brock S, Wen Y, Xiong C, Gharpure K, Hansen JM, Nagaraja AS, Previs RA, Vivas-Mejia, Han HD, Hu W, Mangala LS, Zand B, Stagg, LJ, Ladbury JE, Ozpolat B, Alpay SN, Nishimura M, Stone RL, Matsuo K, Armaiz-Pena GN, Dalton HJ, Danes C, Goodman B, Rodriguez-Aguayo C, Kruger C, Schneider A, Haghpeykar S, Jaladurgam P, Hung MC, Coleman RL, Liu J, Li C, Urbauer D, Lopez-Berestein G, Jackson DB, Sood AK. Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell 28(5):610-622, 2015. e-Pub 2015. PMID: 26481148.
88. Jiang Q, Zhang Q, Wang S, Xie S, Fang W, Liu Z, Liu J, and Yao K. A Fraction of CD133 + CNE2 Cells is made of Giant Cells with Morphological Evidence of Asymmetric Mitosis. J Cancer 6(12):1236-44, 2015. e-Pub 2015. PMID: 26535065.
89. Zhang Y, Liang L, Euscher ED, Liu J, Ramalingam P. Gastric-type mucinous adenocarcinoma of the uterine cervix with neoadjuvant therapy mimicking clear cell carcinoma. Int J Clin Exp Pathol 8(9):11798-803, 2015. e-Pub 2015. PMID: 26617929.
90. Wang B, Hou D, Liu Q, Wu T, Guo H, Zhang X, Zou Y, Liu Z, Liu J, Wei J, Gong Y, Shao C. Artesunate sensitizes ovarian cancer cells to cisplatin by downregulating RAD51. Cancer Biol Ther 16(10):1548-56, 2015. e-Pub 2015. PMID: 26176175.
91. Zhang S, Lu Z, Mao W, Ahmed AA, Yang H, Zhou J, Jennings N, Rodriguez-Aguayo C, Lopez-Berestein G, Miranda R, Qiao W, Baladandayuthapani V, Li Z, Sood AK, Liu J, Le XF, Bast RC. CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis. PLoS One 10(7):e0131833, 2015. e-Pub 2015. PMID: 26146988.
92. Haria D, Trinh BQ, Ko SY, Barengo N, Liu J, Naora H. The Homeoprotein DLX4 Stimulates NF-κB Activation and CD44-Mediated Tumor-Mesothelial Cell Interactions in Ovarian Cancer. Am J Pathol 185(8):2298-308, 2015. e-Pub 2015. PMID: 26067154.
93. Dong R, Liu X, Zhang Q, Jiang Z, Li Y, Wei Y, Li Y, Yang Q, Liu J, Wei JJ, Shao C, Liu Z, Kong B. miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma. Oncotarget 5(21):10816-29, 2014. e-Pub 2014. PMID: 25333261.
94. Sun Y, Hu L, Zheng H, Bagnoli M, Guo Y, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Ji P, Chen K, Sood AK, Mezzanzanica D, Liu J, Sun B, Zhang W. MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J Pathol 235(1):25-36, 2014. e-Pub 2014. PMID: 25230372.
95. Leung CS, Yeung TL, Yip KP, Pradeep S, Balasubramanian L, Liu J, Wong KK, Mangala LS, Armaiz-Pena GN, Lopez-Berestein G, Sood AK, Birrer MJ, Mok SC. Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nat Commun 5:5092, 2014. e-Pub 2014. PMID: 25277212.
96. Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, Zand B, Dalton HJ, Arumugam T, Lee HJ, Han HD, Cho MS, Rupaimoole R, Mangala LS, Sehgal V, Oh SC, Liu J, Lee JS, Coleman RL, Ram P, Lopez-Berestein G, Fidler IJ, Sood AK. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell 26(1):77-91, 2014. e-Pub 2014. PMID: 25026212.
97. Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, Pecot CV, Nick AM, Wu SY, Lee JS, Sehgal V, Ram P, Liu J, Tucker SL, Lopez-Berestein G, Baggerly KA, Coleman RL, Sood AK. Notch3 pathway alterations in ovarian cancer. Cancer Res 74(12):3282-93, 2014. e-Pub 2014. PMID: 24743243.
98. Yang L, Moss T, Mangala LS, Marini J, Zhao H, Wahlig S, Armaiz-Pena G, Jiang D, Achreja A, Win J, Roopaimoole R, Rodriguez-Aguayo C, Mercado-Uribe I, Lopez-Berestein G, Liu J, Tsukamoto T, Sood AK, Ram PT, Nagrath D. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol 10:728, 2014. e-Pub 2014. PMID: 24799285.
99. Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AK. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep 7(2):488-500, 2014. e-Pub 2014. PMID: 24703838.
100. Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, Previs RA, Armaiz-Pena GN, Huang L, Martinez C, Hassell T, Ivan C, Sehgal V, Singhania R, Han HD, Su C, Kim JH, Dalton HJ, Kovvali C, Keyomarsi K, McMillan NA, Overwijk WW, Liu J, Lee JS, Baggerly KA, Lopez-Berestein G, Ram PT, Nawrot B, Sood AK. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun 5:3459, 2014. e-Pub 2014. PMID: 24619206.
101. Zhang S, Mercado-Uribe I, Liu J. Tumor stroma and differentiated cancer cells can be originated directly from polyploid giant cancer cells induced by paclitaxel. Int J Cancer 134(3):508-18, 2014. e-Pub 2014. PMID: 23754740.
102. Zhang S, Mercado-Uribe I, Xing Z, Sun B, Kuang J, Liu J. Generation of cancer stem-like cells through the formation of polyploid giant cancer cells. Oncogene 33(1):116-28, 2014. e-Pub 2014. PMID: 23524583.
103. Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, Bondy M, Liu J, Hunt KK, Keyomarsi K. Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res 16(6):3417, 2014. e-Pub 2014. PMID: 25551582.
104. Zhang S, Mercado-Uribe I, Hanash S, Liu J. iTRAQ-based proteomic analysis of polyploid giant cancer cells and budding progeny cells reveals several distinct pathways for ovarian cancer development. PLoS One 8(11):e80120, 2013. e-Pub 2013. PMID: 24348907.
105. Kang Y, Hu W, Ivan C, Dalton HJ, Miyake T, Pecot CV, Zand B, Liu T, Huang J, Jennings NB, Rupaimoole R, Taylor M, Pradeep S, Wu SY, Lu C, Wen Y, Huang J, Liu J, Sood AK. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst 105(19):1485-95, 2013. e-Pub 2013. PMID: 24062525.
106. Liu Z, Gersbach E, Zhang X, Xu X, Dong R, Lee P, Liu J, Kong B, Shao C, Wei JJ. miR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma. Mol Cancer Res 11(11):1314-25, 2013. e-Pub 2013. PMID: 24045973.
107. Yeung TL, Leung CS, Wong KK, Samimi G, Thompson MS, Liu J, Zaid TM, Ghosh S, Birrer MJ, Mok SC. TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res 73(16):5016-28, 2013. e-Pub 2013. PMID: 23824740.
108. Yang G, Mercado-Uribe I, Multani AS, Sen S, IeM S, Wong KK, Gershenson DM, Liu J. RAS promotes tumorigenesis through genomic instability induced by imbalanced expression of Aurora-A and BRCA2 in midbody during cytokinesis. Int J Cancer 133(2):275-85, 2013. e-Pub 2013. PMID: 23319376.
109. Zhang S, Mercado-Uribe I, Liu J. Generation of erythroid cells from fibroblasts and cancer cells in vitro and in vivo. Cancer Lett 333(2):205-12, 2013. e-Pub 2013. PMID: 23376638.
110. Chen X, Zhang J, Cheng W, Chang DY, Huang J, Wang X, Jia L, Rosen DG, Zhang W, Yang D, Gershenson DM, Sood AK, Bast RC, Liu J. CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer. Int J Gynecol Cancer 23(5):815-22, 2013. e-Pub 2013. PMID: 23669443.
111. Zhang J, Chang B, Liu J. CD44 standard form expression is correlated with high-grade and advanced-stage ovarian carcinoma but not prognosis. Hum Pathol 44(9):1882-9, 2013. e-Pub 2013. PMID: 23664487.
112. Huang J, Zhang J, Li H, Lu Z, Shan W, Mercado-Uribe I, Liu J. VCAM1 expression correlated with tumorigenesis and poor prognosis in high grade serous ovarian cancer. Am J Transl Res 5(3):336-46, 2013. e-Pub 2013. PMID: 23634244.
113. Schauer IG, Zhang J, Xing Z, Guo X, Mercado-Uribe I, Sood AK, Huang P, Liu J. Interleukin-1β promotes ovarian tumorigenesis through a p53/NF-κB-mediated inflammatory response in stromal fibroblasts. Neoplasia 15(4):409-20, 2013. e-Pub 2013. PMID: 23555186.
114. Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, Cogdell D, Nykter M, Broaddus R, Rodriguez-Aguayo C, Lopez-Berestein G, Liu J, Shmulevich I, Sood AK, Chen K, Zhang W. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell 23(2):186-99, 2013. e-Pub 2013. PMID: 23410973.
115. Trachootham D, Chen G, Zhang W, Lu W, Zhang H, Liu J, Huang P. Loss of p53 in stromal fibroblasts promotes epithelial cell invasion through redox-mediated ICAM1 signal. Free Radic Biol Med 58:1-13, 2013. e-Pub 2013. PMID: 23376231.
116. Jia L, Zhang S, Ye Y, Li X, Mercado-Uribe I, Bast RC, Liu J. Paclitaxel inhibits ovarian tumor growth by inducing epithelial cancer cells to benign fibroblast-like cells. Cancer Lett 326(2):176-82, 2012. e-Pub 2012. PMID: 22902993.
117. Zhan Y, Abi Saab WF, Modi N, Stewart AM, Liu J, Chadee DN. Mixed lineage kinase 3 is required for matrix metalloproteinase expression and invasion in ovarian cancer cells. Exp Cell Res 318(14):1641-8, 2012. e-Pub 2012. PMID: 22652451.
118. Xiao X, Zou J, Bui-Nguyen TM, Bai P, Gao L, Liu J, Liu S, Xiao J, Chen X, Zhang X, Wang H. Paris saponin II of Rhizoma Paridis--a novel inducer of apoptosis in human ovarian cancer cells. Biosci Trends 6(4):201-11, 2012. e-Pub 2012. PMID: 23006967.
119. Shan W, Mercado-Uribe I, Zhang J, Rosen D, Zhang S, Wei J, Liu J. Mucinous adenocarcinoma developed from human fallopian tube epithelial cells through defined genetic modifications. Cell Cycle 11(11):2107-13, 2012. e-Pub 2012. PMID: 22592533.
120. Lu W, Hu Y, Chen G, Chen Z, Zhang H, Wang F, Feng L, Pelicano H, Wang H, Keating MJ, Liu J, McKeehan W, Wang H, Luo Y, Huang P. Novel role of NOX in supporting aerobic glycolysis in cancer cells with mitochondrial dysfunction and as a potential target for cancer therapy. PLoS Biol 10(5):e1001326, 2012. e-Pub 2012. PMID: 22589701.
121. Liu Y, Sun Y, Broaddus R, Liu J, Sood AK, Shmulevich I, Zhang W. Integrated analysis of gene expression and tumor nuclear image profiles associated with chemotherapy response in serous ovarian carcinoma. PLoS One 7(5):e36383, 2012. e-Pub 2012. PMID: 22590536.
122. Liu Z, Liu J, Segura MF, Shao C, Lee P, Gong Y, Hernando E, Wei JJ. MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma. J Pathol 228(2):204-15, 2012. e-Pub 2012. PMID: 22322863.
123. Bai P, Xiao X, Zou J, Cui L, Bui Nguyen TM, Liu J, Xiao J, Chang B, Wu J, Wang H. Expression of p14(ARF), p15(INK4b), p16(INK4a) and skp2 increases during esophageal squamous cell cancer progression. Exp Ther Med 3(6):1026-1032, 2012. e-Pub 2012. PMID: 22970012.
124. Zhang J, Chang DY, Mercado-Uribe I, Liu J. Sex-determining region Y-box 2 expression predicts poor prognosis in human ovarian carcinoma. Hum Pathol 43(9):1405-12, 2012. e-Pub 2012. PMID: 22401770.
125. Katayama H, Wang J, Treekitkarnmongkol W, Kawai H, Sasai K, Zhang H, Wang H, Adams HP, Jiang S, Chakraborty SN, Suzuki F, Arlinghaus RB, Liu J, Mobley JA, Grizzle WE, Wang H, Sen S. Aurora kinase-A inactivates DNA damage-induced apoptosis and spindle assembly checkpoint response functions of p73. Cancer Cell 21 doi: 10.1016/j.ccr.2011.12.025(2):196-211, 2012. e-Pub 2012. PMID: 22340593.
126. Ling J, Kang Y, Zhao R, Xia Q, Lee DF, Chang Z, Li J, Peng B, Fleming JB, Wang H, Liu J, Lemischka IR, Hung MC, Chiao PJ. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 21(1):105-20, 2012. e-Pub 2012. PMID: 22264792.
127. Shen Y, Wang Y, Shi Y, Liu J, Liu Y. Clinicopathologic study of endometrial dedifferentiated endometrioid adenocarcinoma: a case report. Int J Clin Exp Pathol 5(1):77-82, 2012. e-Pub 2012. PMID: 22295150.
128. Zhang J, Guo X, Chang DY, Rosen DG, Mercado-Uribe I, Liu J. CD133 expression associated with poor prognosis in ovarian cancer. Mod Pathol 25(3):456-64, 2011. e-Pub 2011. PMID: 22080056.
129. Ligr M, Patwa RR, Daniels G, Pan L, Wu X, Li Y, Tian L, Wang Z, Xu R, Wu J, Chen F, Liu J, Wei JJ, Lee P. Expression and function of androgen receptor coactivator p44/Mep50/WDR77 in ovarian cancer. PLoS One 6(10):e26250, 2011. e-Pub 2011. PMID: 22022581.
130. Huang L, Schauer IG, Zhang J, Mercado-Uribe I, Deavers MT, Huang J, Liu J. The oncogenic gene fusion TMPRSS2: ERG is not a diagnostic or prognostic marker for ovarian cancer. Int J Clin Exp Pathol 4(7):644-50, 2011. e-Pub 2011. PMID: 22076164.
131. Guo X, Liu G, Schauer IG, Yang G, Mercado-Uribe I, Yang F, Zhang S, He Y, Liu J. Overexpression of the β subunit of human chorionic gonadotropin promotes the transformation of human ovarian epithelial cells and ovarian tumorigenesis. Am J Pathol 179(3):1385-93, 2011. e-Pub 2011. PMID: 21763678.
132. Stevens EV, Banet N, Onesto C, Plachco A, Alan JK, Nikolaishvili-Feinberg N, Midkiff BR, Kuan PF, Liu J, Miller CR, Vigil D, Graves LM, Der CJ. RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis. Small GTPases 2(4):202-210, 2011. e-Pub 2011. PMID: 22145092.
133. Cheng X, Yang G, Schmeler KM, Coleman RL, Tu X, Liu J, Kavanagh JJ. Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy. Gynecol Oncol 121(2):323-7, 2011. e-Pub 2011. PMID: 21277011.
134. Wu S, Wang L, Guo W, Liu X, Liu J, Wei X, Fang B. Analogues and derivatives of oncrasin-1, a novel inhibitor of the C-terminal domain of RNA polymerase II and their antitumor activities. J Med Chem 54(8):2668-79, 2011. e-Pub 2011. PMID: 21443218.
135. Yang G, Xiao X, Rosen DG, Cheng X, Wu X, Chang B, Liu G, Xue F, Mercado-Uribe I, Chiao P, Du X, Liu J. The biphasic role of NF-kappaB in progression and chemoresistance of ovarian cancer. Clin Cancer Res 17(8):2181-94, 2011. e-Pub 2011. PMID: 21339307.
136. Yang F, Guo X, Yang G, Rosen DG, Liu J. AURKA and BRCA2 expression highly correlate with prognosis of endometrioid ovarian carcinoma. Mod Pathol 24(6):836-45, 2011. e-Pub 2011. PMID: 21441901.
137. Zhan Y, Modi N, Stewart AM, Hieronimus RI, Liu J, Gutmann DH, Chadee DN. Regulation of mixed lineage kinase 3 is required for Neurofibromatosis-2-mediated growth suppression in human cancer. Oncogene 30(7):781-9, 2011. e-Pub 2011. PMID: 20890305.
138. Wu J, Liu Z, Shao C, Gong Y, Hernando E, Lee P, Narita M, Muller W, Liu J, Wei JJ. HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes. Cancer Res 71(2):349-59, 2011. e-Pub 2011. PMID: 21224353.
139. Raghunath A, Adamus G, Bodurka DC, Liu J, Schiffman JS. Cancer-associated retinopathy in neuroendocrine carcinoma of the fallopian tube. (Cover picture of issue). J Neurophthalmol 30(3):252-4, 2010. e-Pub 2010. PMID: 20724944.
140. Yang G, Rosen DG, Liu G, Yang F, Guo X, Xiao X, Xue F, Mercado-Uribe I, Huang J, Lin SH, Mills GB, Liu J. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. (Cover Picture). Clin Cancer Res 16(15):3875-86, 2010. e-Pub 2010. PMID: 20505188.
141. Yang G, Chang B, Yang F, Guo X, Cai KQ, Xiao XS, Wang H, Sen S, Hung MC, Mills GB, Chang S, Multani AS, Mercado-Uribe I, Liu J. Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. Clin Cancer Res 16(12):3171-81, 2010. e-Pub 2010. PMID: 20423983.
142. Stevens EV, Carpenter AW, Shin JH, Liu J, Der CJ, Schoenfisch MH. Nitric oxide-releasing silica nanoparticle inhibition of ovarian cancer cell growth. Mol Pharm 7(3):775-85, 2010. e-Pub 2010. PMID: 20205473.
143. Liu G, Yang G, Chang B, Mercado-Uribe I, Huang M, Zheng J, Bast RC, Lin SH, Liu J. Stanniocalcin 1 and ovarian tumorigenesis. (This paper has been featured in “Publication Spotlight" on the M. D. Anderson Faculty Resources site in the week of May 21, 2010). J Natl Cancer Inst 102(11):812-27, 2010. e-Pub 2010. PMID: 20484106.
144. Wei X, Guo W, Wu S, Wang L, Huang P, Liu J, Fang B. Oxidative stress in NSC-741909-induced apoptosis of cancer cells. J Transl Med 8:37, 2010. e-Pub 2010. PMID: 20398386.
145. Zheng J, Mercado-Uribe I, Rosen DG, Chang B, Liu P, Yang G, Malpica A, Naora H, Auersperg N, Mills GB, Bast RC, Liu J. Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. Cell Cycle 9(1):140-6, 2010. e-Pub 2010. PMID: 20016289.
146. Wei JJ, Wu J, Luan C, Yeldandi A, Lee P, Keh P, Liu J. HMGA2: a potential biomarker complement to P53 for detection of early-stage high-grade papillary serous carcinoma in fallopian tubes. Am J Surg Pathol 34(1):18-26, 2010. e-Pub 2010. PMID: 19898227.
147. Rosen DG, Zhang Z, Chang B, Wang X, Lin E, Liu J. Low membranous expression of beta-catenin and high mitotic count predict poor prognosis in endometrioid carcinoma of the ovary. Mod Pathol 23(1):113-22, 2009. e-Pub 2009. PMID: 19820688.
148. Ding WX, Ni HM, Gao W, Chen X, Kang JH, Stolz DB, Liu J, Yin XM. Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy. Mol Cancer Ther 8(7):2036-45, 2009. e-Pub 2009. PMID: 19584239.
149. Xia W, Wei Y, Du Y, Liu J, Chang B, Yu YL, Huo LF, Miller S, Hung MC. Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol Carcinog 48(7):610-7, 2009. e-Pub 2009. PMID: 19058255.
150. Wei X, Guo W, Wu S, Wang L, Lu Y, Xu B, Liu J, Fang B. Inhibiting JNK dephosphorylation and induction of apoptosis by novel anticancer agent NSC-741909 in cancer cells. J Biol Chem 284(25):16948-55, 2009. e-Pub 2009. PMID: 19414586.
151. Levina VV, Nolen B, Su Y, Godwin AK, Fishman D, Liu J, Mor G, Maxwell LG, Herberman RB, Szczepanski MJ, Szajnik ME, Gorelik E, Lokshin AE. Biological significance of prolactin in gynecologic cancers. Cancer Res 69(12):5226-33, 2009. e-Pub 2009. PMID: 19491263.
152. Tung CS, Mok SC, Tsang YT, Zu Z, Song H, Liu J, Deavers MT, Malpica A, Wolf JK, Lu KH, Gershenson DM, Wong KK. PAX2 expression in low malignant potential ovarian tumors and low grade ovarian serous carcinomas. Mod Pathol 22(9):1243-50, 2009. e-Pub 2009. PMID: 19525924.
153. Xiao X, Bai P, Bui Nguyen TM, Xiao J, Liu S, Yang G, Hu L, Chen X, Zhang X, Liu J, Wang H. The antitumoral effect of Paris Saponin I associated with the induction of apoptosis through the mitochondrial pathway. Mol Cancer Ther, 2009. e-Pub 2009. PMID: 19435869.
154. Wang S, Zhou J, X-Y W, J-W H, J-Z C, Zhang X-M Jin H, Liu L, Y-F Z, Liu J, Y-Q D, J-M AL. SATB2 is an independent favorable prognostic marker of colorectal cancer. J Pathol, 2009. e-Pub 2009.
155. Chang B, Liu G, Xue F, Rosen DG, Xiao L, Wang X, Liu J. ALDH1 Expression Correlates with Favorable Prognosis in Ovarian Cancers. Mod Pathol 22(6):817-23, 2009. e-Pub 2009. PMID: 19329942.
156. Chang B, Liu G, Yang G, Mercado-Uribe I, Huang M, Liu J. REDD1 is required for RAS-mediated transformation of human ovarian epithelial cells. Cell Cycle 8(5):780-6, 2009. e-Pub 2009. PMID: 19221489.
157. Guo W, Wu S, Wang L, Wang RY, Wei X, Liu J, Fang B. Interruption of RNA processing machinery by a small compound 1-[(4-chlorophenyl) methyl]-1H-indole-3-carboxaldehyde (oncrasin-1). Mol Cancer Ther 8(2):441-8, 2009. e-Pub 2009. PMID: 19208825.
158. Mulligan P, Westbrook TF, Ottinger M, Chang B, Pavlova N, Macia M, Y-J S, Barretina J, Liu J, Howley PM, Elledge SJ, and Shi Y. CDYL bridges REST and histone methyltransferases for gene repression and tumor suppression. Mol Cell 32(5):243-254, 2008. e-Pub 2008. PMID: 19061646.
159. Yeung BH, Kwan BW, He QY, Lee AS, Liu J, Wong AS. Glucose-regulated protein 78 as a novel effector of BRCA1 for inhibiting stress-induced apoptosis. Oncogene 27(53):6782-9, 2008. e-Pub 2008. PMID: 18776923.
160. Cao Y, Li Y, Edelweiss M, Arun B, Rosen D, Resetkova E, Wu Y, Liu J, Sahin A, Albarracin CT. Loss of annexin A1 expression in breast cancer progression. Appl Immunohistochem Mol Morphol 16(6):530-4, 2008. e-Pub 2008. PMID: 18776816.
161. Yu S, Murph MM, Lu Y, Liu S, Hall HS, Liu J, Stephens C, Fang X, Mills GB. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 100(22):1630-42, 2008. e-Pub 2008. PMID: 19001604.
162. Bartholomeusz C, Rosen D, Wei C, Kazansky A, Yamasaki F, Takahashi T, Itamochi H, Kondo S, Liu J, Ueno NT. PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival. Cancer Res 68(22):9302-10, 2008. e-Pub 2008. PMID: 19010903.
163. Posligua L, Malpica A, Liu J, Brown J, Deavers MT. Combined large cell neuroendocrine carcinoma and papillary serous carcinoma of the endometrium with pagetoid spread. Arch Pathol Lab Med 132(11):1821-4, 2008. e-Pub 2008. PMID: 18976022.
164. Simon RA, di Sant'Agnese PA, Huang LS, Xu H, Yao JL, Yang Q, Liang S, Liu J, Yu R, Cheng L, Oh WK, Palapattu GS, Wei J, Huang J. CD44 Expression is a Feature of Prostatic Small Cell Carcinoma and Distinguishes it from its Mimickers. Hum Pathol 40(2):252-8, 2008. e-Pub 2008. PMID: 18835619.
165. Feng W, Duan X, Liu J, Xiao J, Brown RE. Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions. Int J Clin Exp Pathol 2(3):249-60, 2008. e-Pub 2008. PMID: 19079619.
166. Guo W, Wu S, Liu J, Fang B. Identification of a small molecule with synthetic lethality for K-Ras and protein kinase Ciota. Cancer Res 68(18):7403-8, 2008. e-Pub 2008. PMID: 18794128.
167. Nair SS, Rajhans R, Piteshwara RP, Liu J, Seetharaman B, Le XF, Burrow ME, Nelly A, Tekmal RR, Broaddus RR, Vadlamudi RK. Role of PELP1/MNAR signaling in ovarian tumorigenesis. Cancer Res 68(12):4902-9, 2008. e-Pub 2008. PMID: 18559538.
168. Wang XH, Urvalek AM, Liu J, Zhao JH. Activation of KLF8 transcription by FAK in human ovarian epithelial and cancer cells. J Biol Chem 283(20):13934-42, 2008. e-Pub 2008. PMID: 18353772.
169. Wang DM, Zhao ZW, Caperell-Grant A, Yang A, Liu J, Bigsby R, Xu Y. S1P differentially regulates migration of human ovarian cancer and human ovarian surface epithelial cells. Mol Cancer Therapeutics 7(7):1993-2002, 2008. e-Pub 2008. PMID: 18645009.
170. Demizu Y, Sasaki R, Trachootham D, Pelicano H, Colacino JA, Liu J, and Huang P. Alterations of cellular redox state during NNK-induced malignant transformation and resistance to radiation, antioxidants & redox signaling. Antioxid Redox Signal 10(5):951-61, 2008. e-Pub 2008. PMID: 18257743.
171. Feng W, Marquez RT, Lu Z, Liu J, Lu KH, Issa JP, Fishman DM, Yu Y, Bast RC. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 112(7):1489-502, 2008. e-Pub 2008. PMID: 18286529.
172. Liu S, Fang F, Hall H, Yu S, Smith D, Lu Z, Fang D, Liu J, Stephens LC, Woodgett JR, Mills GB. Homozygous deletion of glycogen synthase kinase 3β bypasses senescence allowing Ras transformation of primary murine fibroblasts. Proc Natl Acad Sci USA 105(13):5248-53, 2008. e-Pub 2008. PMID: 18367674.
173. Zecchini S, Bianchi M, Colombo N, Fasani R, Goisis G, Casadio C, Viale G, Liu J, Herlyn M, Godwin AK, Nuciforo PG, Cavallaro U. The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium. Implication for ovarian cancer progression. Cancer Res 68(4):1110-8, 2008. e-Pub 2008. PMID: 18281486.
174. Li Y, Li CH, Ye HH, Chen F, Melamed J, Yi P, Liu J, Wang ZX, Tsou HC, Wei JJ, Garabedian MJ, Lee P Walden P. Decrease in stromal androgen receptor associates with androgen-independent disease and promotes prostate cancer cell proliferation and invasion. J. Mol & Cell Med 12(6B):2790-8, 2008. e-Pub 2008. PMID: 18266956.
175. Kubba LA, McCluggage WG, Liu J, Malpica A, Euscher E, Silva E, Deavers MT. Thyroid transcription factor-1 expression in ovarian epithelial neoplasms. Modern Pathol 21(4):485-90, 2008. e-Pub 2008. PMID: 18246044.
176. Zhai QJ, Rosen DG, Lu K, Liu J. Loss of DNA mismatch repair protein hMSH6 in ovarian cancer is histotype-specific. Int J Clin Exp Pathol 1(6):502-9, 2008. e-Pub 2008. PMID: 18787632.
177. Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay NV, Albarracin C, Yu D, Abbruzzese JL, Mills GB, Bast RC, Hortobagyi GN, Hung MC. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian and pancreatic cancers. Mol Carcinog 47(9):701-6, 2008. e-Pub 2008. PMID: 18176935.
178. Bartholomeusz C, Rosen D, Wei C, Yamasaki F, Takahashi T, Itamochi H, Kondo S, Liu J, Ueno NT. Novel ERK regulator phosphoprotein PEA-15, which induces autophagy in human ovarian cancer cells, is associated with prolonged overall survival in women with primary epithelial ovarian cancer 68(22):9302-9310, 2008. e-Pub 2008.
179. Cao Y, Li YX, Edelweiss M, Arun B, Wu Y, Rosen DG, Liu J, Sahin A, Albarracin CT. Dysregulation of annexin A1 in development and progression of breast cancer. Appl Immunohistochem & Mol Morphol 15(4):451-5, 2008. e-Pub 2008.
180. Gokhale S, Rosen D, Sneige N, Diaz LK, Resetkova E, Sahin A, Liu J, Albarracin CT. Assessment of two automated imaging systems in evaluating estrogen receptor status in breast carcinoma. Appl Immunohistochem Mol Morphol 15(4):451-5, 2007. e-Pub 2007. PMID: 18091390.
181. Milam MR, Gabel SF, Milam RA, Liu J, Ramirez PT. Neoadjuvant bleomycin, etoposide, and cisplatin in adult neuroblastoma arising from the broad ligament of the uterus. Gynecol Oncol 107(2):350-4, 2007. e-Pub 2007. PMID: 17881040.
182. Zhang ZH, Singh M, Rosen DG, Yang G, Liu J. Activation of BTAK expression in primary ovarian surface epithelial cells from prophylactic ovaries. Modern Pathol 20(10):1078-84, 2007. e-Pub 2007. PMID: 17673924.
183. Feng W, Xiao J, Zhang Z, Rosen DG, Liu J, Duan X. Senescence and Apoptosis in Carcinogenesis of Cervical Squamous Carcinoma. Modern Pathol 20(9):961-6, 2007. e-Pub 2007. PMID: 17632454.
184. Young T, Rosen DG, Mei F, Li N, Liu J, Cheng X. Up-regulation of TSG101 conveys poor prognosis through suppression of p21 expression in ovarian cancers. Clin Cancer Res 13(13):3848-54, 2007. e-Pub 2007. PMID: 17606716.
185. Hara F, Samuel S, Liu J, Rosen D, Langley RR, Naora H. A homeobox gene related to Drosophila Distal-less promotes ovarian tumorigenicity by inducing expression of vascular endothelial growth factor and fibroblast growth factor-2. Am J Pathol 170(5):1594-606, 2007. e-Pub 2007. PMID: 17456765.
186. Nanjundan M, Nakayama Y, Cheng KW, Lahad J, Liu J, Lu K, Kuo WL, Smith-McCune K, Fishman D, Gray JW, Mills GB. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res 67(7):3074-84, 2007. e-Pub 2007. PMID: 17409414.
187. Yang G, Rosen DG, Colacino J, Mercado-Uribe I, Liu J. Disruption of the retinoblastoma pathway by small interfering RNA and ectopic expression of the catalytic subunit of telomerase leads to immortalization of human ovarian surface epithelial cells. Oncogene 26(10):1492-8, 2007. e-Pub 2007. PMID: 16953228.
188. Wang-Joanning F, Liu J, Rosen DG, Chen DT, Rycaj K, Huang M. Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer. Int J Cancer 120(1):81-90, 2007. e-Pub 2007. PMID: 17013901.
189. Feng W She L, Wen S, Rosen DG, Jeroslav J, Hu X, Huang S, Huang M, Liu J, Sahin AA, Hunt KK, Bast RC, Jr, Shen Y, Issa J-P J, Yu Y. Correlation between two panels of CpG methylation profiles and hormone receptor status in breast cancer. Breast Cancer Res 9(4):R57, 2007. e-Pub 2007. PMID: 17764565.
190. Rosen DG, Mercado-Uribe I, Yang G, Bast RC, Amin H, Lai R, Liu J. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer 107(11):2730-40, 2006. e-Pub 2006. PMID: 17063503.
191. Young T, Mei F, Rosen DG, Yang G, Liu J, Cheng X. Up-regulation of tumor susceptibility gene 101 protein in ovarian carcinomas revealed by proteomic analyses. Mol and Cell Proteomics 6(2):294-304, 2006. e-Pub 2006. PMID: 17110434.
192. Liu B, Park E, Zhu F, Bustos T, Liu J, Shen J, Fischer SM, Hu Y. A critical role for I kappaB kinase alpha in the development of human and mouse squamous cell carcinomas. Proc Natl Acad Sci U S A 103(46):17202-7, 2006. e-Pub 2006. PMID: 17079494.
193. Wen X, Yang G, Lammayot A, Mao W, Thorton A, Liu J, Jr BR, X-F AL. Her2 signaling modulates the equilibrium between pro- and anti-angiogenic factors via two distinct pathways: Implication for Her2 targeted antibody therapy. Oncogene 25(52):6986-96, 2006. e-Pub 2006. PMID: 16715132.
194. Yang G, Rosen DG, Zhang Z, Bast RC, Jr, Mills GB, Mercado-Uribe I, Liu J. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A 103(44):16472-7, 2006. e-Pub 2006. PMID: 17060621.
195. Trachootham D, Zhou Y, Hui Z, Demizu Y, Chen C, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J, Huang P. Selective killing of oncogenic-transformed cells through ROS-mediated mechanism by β-phenylethyl isothiocyanate. Cancer Cell 10(3):243-251, 2006. e-Pub 2006. PMID: 16959615.
196. Rosen, DG, Cai KQ, Lutha R, Liu J. Immunohistochemical staining of hMLH1 and hMSH2 reflects microsatellite instability status in ovarian carcinoma. Modern Pathol 19(11):1414-20, 2006. e-Pub 2006. PMID: 16941012.
197. Yang G, Rosen DG, Mercado-Uribe I, Colacino JA, Mills GB, Bast RC, Zhou C, Liu J. Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. Carcinogenesis 28(1):174-82, 2006. e-Pub 2006. PMID: 16829690.
198. Culton LK, Deavers MT, Silva EG, Liu J, Malpica A. Endometrioid carcinoma simultaneously involving the uterus and the fallopian tube: a clinicopathologic study of 13 cases. Am J Surg Pathol 30(7):844-9, 2006. e-Pub 2006. PMID: 16819326.
199. Zhang ZH, Rosen DG, Yao JJ, Huang J, Liu J. Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases during prostate cancer progression. Modern Pathol 19(10):1339-43, 2006. e-Pub 2006. PMID: 16799475.
200. Teraishi F, Zhang L, Guo W, Dong F, Davis JJ, Sasazuki T, Shirasawa S, Liu J, Fang B. Activation of sterile20-Like kinase 1 (MST1) in proteasome inhibitor bortezomib-induced apoptosis in oncogenic K-ras-transformed cells. Cancer Res 66(12):6072-9, 2006. e-Pub 2006. PMID: 16778179.
201. Rosen DG, Yang G, Deavers MT, Malpica A, Kavanagh JJ, Mills GB, Liu J. Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer 106(9):1925-32, 2006. e-Pub 2006. PMID: 16568440.
202. Lu Z, Luo RZ, Peng H, Rosen DG, Atkinson EN, Warneke C, Huang M, Nishmoto A, Liu J, Liao WS, Yu Y, Jr BR. Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer. Clin Cancer Res 12(8):2404-13, 2006. e-Pub 2006. PMID: 16638845.
203. Wang-Johanning F, Huang M, Liu J, Barnhart KF, Satterfield WC, Johanning G. Stromal-epithelial cell interactions and ovarian tumor progression. Int J Cancer 66(8):396, 2006. e-Pub 2006.
204. Kuo M, Wei Y, Yang Y, Tatebe S, Liu J, Troncoso P, Sahin A, Ro JY, Hamilton SR, Savaraj N. Association of fragile site-associated (FSA) gene expression with epithelial differentiation and tumor development. Biochem & Biophys Res Comm 340(3):887-93, 2006. e-Pub 2006. PMID: 16386706.
205. Chang KH, Albarracin C, Luthra R, Zheng W, Wang L, Malpica A, Deavers MT, Silva EG, Liu J. Discordant genetic changes in ovarian and endometrial endometrioid carcinomas: A potential diagnostic pitfall. Int J Gynecol Cancer 16(1):178-182, 2006. e-Pub 2006. PMID: 16445630.
206. Wang H, Rosen DG, Wang H, Fuller G, Zhang W, Liu J. IGFBPII and IGFBPV expression and prognostic significance in epithelial ovarian cancer. Modern Pathol 19(9):1149-56, 2006. e-Pub 2006.
207. Prowse AH, Manek S, Varma R, Liu J, Godwin AK, Maher ER, Tomlinson Ian PM, Kennedy SH. Molecular genetic evidence that endometriosis is a precursor of ovarian cancer. Int J Cancer 119(3):556-62, 2005. e-Pub 2005. PMID: 16384911.
208. Mei F, Young T, Liu J, Cheng X. RAS-mediated epigenetic interaction of OPCML in oncogenic transformation of human ovarian surface epithelial cells. FESEB J 20(3):497-9, 2005. e-Pub 2005. PMID: 16384911.
209. Yoshida H, Liu J, Cheng W, Rosen DG, Naora H. AIB1, a homolog of Taiman that controls cell migration in the Drosophila ovary, regulates migration of human ovarian cancer cells. Mol Cell Endocrinol 245(1-2):77-85, 2005. e-Pub 2005. PMID: 16298470.
210. Zhou Y, Garcia-Prieto C, Carney DA, Pelicano H, Kang Y, Yu W, Lou C, Kondo S, Liu J, Harris DM, Estrov Z, Keating MJ, Jin Z, Huang P. OSW-1 exerts potent anticancer activity by causing mitochondrial damage. J Natl Cancer Institute 97:1781-5, 2005. e-Pub 2005. PMID: 16333034.
211. Wang X, Tangjitgamol S, Liu J, Kavanagh JJ. Response of recurrent uterine high-grade malignant mixed mullerian tumor to letrozole. Int J Gynecol Cancer 15(6):1243-8, 2005. e-Pub 2005. PMID: 16343224.
212. Zhou C, Huang P, Liu J. The carboxyl-terminal of BRCA1 is required for subnuclear assembly of RAD51 after treatment with cisplatin but not ionizing radiation in human breast and ovarian cancer cells. Biochem Biophys Res Commun 336(3):952-960, 2005. e-Pub 2005. PMID: 16165098.
213. Boerboom D, Paquet M, Hsieh M, Liu J, Behringer RR, Sirois J, Taketo MM, Richards JS. Misregulation of Wnt/β-catenin signaling plays a key role in ovarian granulosa cell tumorigenesis. Cancer Res 65(20):9206-15, 2005. e-Pub 2005. PMID: 16230381.
214. Hu Y, Rosen DG, Zhou Y, Yang G, Liu J, Huang P. MnSOD expression in ovarian cancer: Role in cell proliferation and response to oxidative stress. J Biol Chem 280(47):39485-92, 2005. e-Pub 2005. PMID: 16179351.
215. Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, Atkinson EN, Smith D, Hartmann L, Fishman D, Berchuck A, Whitaker R, Gershenson DM, Mills GB, Bast RC, Jr, Lu KH. Patterns of gene expression distinguish histotypes of epithelial ovarian cancer that correlate with those in normal fallopian tube, endometrium and colon. Clin Cancer Res 11(17):6116-26, 2005. e-Pub 2005. PMID: 16144910.
216. Lee P, Zhu CC, Sadick NS, Diwan AH, Zhang PS, Liu JS, Prieto VG. Expression of androgen receptor coactivator ARA70/ELE1 in androgenic alopecia. J Cutan Pathol 32(8):567-71, 2005. e-Pub 2005. PMID: 16115056.
217. Eder AM, Sui X, Rosen DG, Nolden H, Cheng KW, Lahad JP, Kango-Singh M, Lu KH, Warneke CL, Atkinson EN, W-L K, Gray JW, Yin J, Liu J, Halder G, Mills GB. Atypical PKC iota is implicated as a novel oncogene contributing to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci USA 102(35):1251-24, 2005. e-Pub 2005. PMID: 16116079.
218. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 99(2):267-77, 2005. e-Pub 2005. PMID: 16061277.
219. Hoestra AV, Riben MW, Frumovitz M, Liu J, Ramirez PT. Well-differentiated papillary mesothelioma of the peritoneum: A pathological analysis and review of literature. Gynecol Oncol 98(1):161-67, 2005. e-Pub 2005. PMID: 15894368.
220. Cheng W, Liu J, Yoshida H, Rosen DG, Naora H. Morphogenesis of epithelial ovarian cancer is controlled by HOX genes that specify regional identity in the female reproductive tract. Nat Med 11(5):531-537, 2005. e-Pub 2005. PMID: 15821746.
221. Lee EJ, Mircean C, Shmulevich I, Wang H, Liu J, Niemisto A, Kavanagh JJ, Lee JH, Zhang W. Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion. Mol Cancer 4(1):7, 2005. e-Pub 2005. PMID: 15686601.
222. Rosen DG, Yang G, Cai KQ, Bast RC, Jr, Gershenson DM, Silva EG, Liu J. Subcellular localization of p27kip predicts poor prognosis in human ovarian cancer. Clin Cancer Res 15(11):632-7, 2005. e-Pub 2005. PMID: 15701850.
223. Young T, Mei F, Liu J, Jr BR, Kurosky A, and Cheng X. Probing H-Ras-mediated oncogenic transformation by functional proteomics in a genetically defined human ovarian cancer model. Oncogene 24:6174-84, 2005. e-Pub 2005.
224. Lee P, Rosen DG, Zhu CC, Silva EG, Liu J. Progesterone receptor expression as an independent prognostic marker in ovarian cancer revealed by tissue microarray. Gynecol Oncol 96(3):671-7-1026, 2005. e-Pub 2005.
225. Nunez MI, Rosen DG, Ludes-Meyers JH, Abba MC, Kil H, Page R, Klein-Szanto A JP, Godwin AK, Liu J, Mills GB, and Aldaz CM. Loss of WWOX protein expression in ovarian carcinomas correlates with poor outcome and specific histotypes. BMC Cancer 5(1):64, 2005. e-Pub 2005.
226. Albarracin CT, Silva EG, Malpica A, Luthra R, Liu J. The role of hMSH3 and hMSH6 in ovarian endometrioid carcinoma and the relationship with microsatellite instability phenotype. Oncol Reports 12(6):1217-1219, 2004. e-Pub 2004. PMID: 15547740.
227. Ramalingam P, Malpica A, Silva EG, Gershenson DM, Liu J, Deavers MT. The Use of cytokeratin 7 and EMA in differentiating ovarian yolk sac tumors from endometrioid and clear cell carcinomas. Am J Surg Pathol 28(11):1499-505, 2004. e-Pub 2004. PMID: 15489654.
228. Cheng KW, Lahad JP, W-L K, Lapuk A, Yamada K, Auersperg N, Liu J, Smith-McCune K, Lu KH, Fishman D, Gray JW, Mills GB. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 10(11):1499-1505, 2004. e-Pub 2004. PMID: 15502842.
229. Rosen DG, Wang L, Jain AN, Lu K, Luo R, Yu Y, Liu J, Bast RC Jr. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression free survival. Clin Cancer Res 10(19):6559-66, 2004. e-Pub 2004. PMID: 15475444.
230. Young TW, Mei FC, Yang G, Thompson-Lanza JA, Liu J, Cheng X. Activation of anti-oxidant pathways in RAS-mediated oncogenic transformation of human surface ovarian epithelial cells revealed by functional proteomics and mass spectrometry. Cancer Res 64(13):4577-84, 2004. e-Pub 2004. PMID: 15231669.
231. Yoshisa H, Cheng W, Hung J, Montell D, Geisbrecht E, Rosen DG, Liu J, Naora H. Lessons from border cell migration in the Drosophila ovary: A role for myosin VI in the migration of human ovarian cancer cells. Proc Natl Acad Sci USA 101(21):8144-9, 2004. e-Pub 2004. PMID: 15146066.
232. Silver DL, Naora H, Liu J, Cheng W, Montell DJ. Activated STAT3 localizes to focal adhesions and promotes ovarian cancer cell migration. Cancer Res 64(10):3550-8, 2004. e-Pub 2004. PMID: 15150111.
233. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, Smith D, Hartmann L, Fishman D, Berchuck A, Schmandt R, Whitaker R, Gershenson DM, Mills G, Bast RC Jr. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10(10):3291-300, 2004. e-Pub 2004. PMID: 15161682.
234. Cai KQ, Albarracin C, Rosen DG, Zhong R, Zheng WX, Luthra R, Broaddus R, Liu J. Microsatellite instability and alteration of expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. Hum Pathol 35(5):552-9, 2004. e-Pub 2004. PMID: 15138928.
235. Liu J, Baykal A, Fung K, Thompson-Lanza JA, Hoque A, Lippman SM, Sahin A. Human telomerase reverse transcriptase mRNA is highly expressed in normal breast tissues and down-regulated in ductal carcinoma in situ. Int J Oncol 24(4):879-84, 2004. e-Pub 2004. PMID: 15010825.
236. Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, Marquez RT, Auersperg N, Yu Y, Hahn WC, Mills GB, Bast RC Jr. A genetically defined model for human ovarian cancer. Cancer Res 64(5):1655-63, 2004. e-Pub 2004. PMID: 14996724.
237. Gu J, Zhang L, Swisher SG, Liu J, Roth JA, Fang B. Induction of p53-regulated genes in lung cancer cells: implications of the mechanism for adenoviral p53-medated apoptosis. Oncogene 23(6):1300-7, 2004. e-Pub 2004. PMID: 14676844.
238. Yang G, Cai KQ, Thompson-Lanza JA, Bast RC, Jr, Liu J. Inhibition of breast and ovarian tumor growth through multiple signaling pathways using retrovirus-mediated siRNA silencing against Her-2/neu gene expression. J Biol Chem 279(6):4339-45, 2004. e-Pub 2004. PMID: 14625284.
239. Baykal A, Thompson TA, X-C X, Hahn, WC, Deavers MT, Malpica A, Gershenson DM, Silva EG, Liu J. In situ human telomerase reverse transcriptase expression pattern in normal and neoplastic ovarian tissues. Oncol Reports 11(2):297-302, 2004. e-Pub 2004. PMID: 14719058.
240. Liu J, Albarracin C, K-H C, Thompson-Lanza JA, Zheng WX, Gershenson DM, Broaddus R, Luthra R. Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. Mod Pathol 17(1):75-80, 2004. e-Pub 2004. PMID: 14631366.
241. Vidal CI, Mintz PJ, Lu K, Ellis LM, Manenti L, Giavazzi R, Gershenson DM, Broaddus R, Liu J, Arap W, and Pasqualini R. An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies in ascites from ovarian cancer patients. Oncogene 25(55):8859-67, 2004. e-Pub 2004.
242. Rosen DG, Huang X, Deavers MT, Malpica A, Silva EG, Liu J. Validation of tissue microarray in human ovarian cancer. Mod Pathol 17(7):790-7, 2004. e-Pub 2004.
243. Hileman EO, Liu J, Albitar M, Keating MJ, Huang P. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother and Pharmacol 53(3):209-19, 2003. e-Pub 2003. PMID: 14610616.
244. Cao SN, Chang KH, Luthra R, Liu J. Frameshift mutations in the bax gene are not involved in development of ovarian endometrioid carcinoma. Mod Pathol 16(10):1048-52, 2003. e-Pub 2003. PMID: 14559989.
245. Santillan A, Kavanagh JJ, Liu J, Ramirez RT. Vulvar Langerhans Cell Histiocytosis: A case report and review of literature. Gynecol Oncol 91(1):241-6, 2003. e-Pub 2003. PMID: 14529688.
246. Wang L, Hoque A, Luo RZ, Yuan J, Liu J, Sahin AA, Lippman SM, Jr BR, Yu Y. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. Clin Cancer Res 9, 2003. e-Pub 2003. PMID: 14506155.
247. Yang G, Thompson JA, Fang B, Liu J. Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumor growth in a model of human ovarian cancer. Oncogene 22(36):5694-701, 2003. e-Pub 2003. PMID: 12944918.
248. Kabbani W, Deavers MT, Malpica A, Burke TW, Liu J, Ordonez NG, Silva EG. Uterine tumor resembling ovarian sex cord tumor presenting as a cervical mass: A case report with tubular pattern mimicking cervical adenocarcinoma. Int J Gyn Pathol 22(3):297-302, 2003. e-Pub 2003. PMID: 12819400.
249. Wang L, Deavers MT, Malpica A, Silva EG, Liu J. Tissue macroarray: A simple and cost-effective method for high throughput studies. Appl Immunohistochem & Mol Morphol 11(2):174-6, 2003. e-Pub 2003. PMID: 12778004.
250. Huang X, Lin T, Gu J, Zhang L, Roth JA, Liu J, Fang B. Cell to cell contact required for bystander effect of the TNF-related apoptosis-inducing ligand (TRAIL) gene. Int J Oncol 22(6):1241-5, 2003. e-Pub 2003. PMID: 12738989.
251. Sawh RN, Malpica A, Deavers MT, Liu J, Silva EG. Benign cystic mesothelioma of the peritoneum: A clinicopathologic study of 17 Cases with immunohistochemical analysis of estrogen and progesterone receptor status. Hum Pathol 34(4):369-74, 2003. e-Pub 2003. PMID: 12733118.
252. Zhou C, Liu J. Inhibition of the catalytic subunit of human telomerase expression by BRCA1 in human ovarian cancer cell lines. Biochem & Biophys Res Commun 303(1):130-6, 2003. e-Pub 2003. PMID: 12646176.
253. Deavers MT, Malpica A, Liu J, Broaddus R, and Silva EG. Ovarian sex-cord stromal tumors, an immunohistochemical study including a comparison of calretinin and inhibin. Mod Pathol 16(6):584-90, 2003. e-Pub 2003.
254. Zhou C, Smith JL, Liu J. Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Oncogene 22:2396-404, 2003. e-Pub 2003.
255. Fu L, Pelicano H, Liu J, Huang P, and Lee CC. The circadian gene mPer2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111(1):41-50, 2002. e-Pub 2002. PMID: 12372299.
256. X-F H, T-Y L, Gu J, L-D Z, Roth JA, Yu Y, Liu J, Fang B. Combined therapy of the TRAIL and Bax genes prolonged survival of animals with ovarian cancer xenograft. Gene Ther 9:1379-86, 2002. e-Pub 2002. PMID: 12365003.
257. Steele-Perkins G, Fang W, X-H Y, Van Gele M, Carling T, Gu J, Buyse IM, Fletcher JA, Liu J, Bronson R, Chadwick RB, de la Chapelle A, X-K Z, Speleman F, Huang A. Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein-methyltransferase superfamily. Genes & Dev 15(17):2250-62, 2001. e-Pub 2001. PMID: 11544182.
258. Zu Y, Perle MA, Yan Z, Liu J, Kumar A, Waisman J. Chromosomal abnormalities and p53 gene mutation in a cardiac angiosarcoma. Appl Immunohistochem Mol Morphol 9(1):24-8, 2001. e-Pub 2001. PMID: 11277410.
259. S-H L, Zhang W, J-J C, Y-S C, S-H L, J-W K, Hu L, Xu J, Liu J, J-H AL. Overexpression of the thymosin β-10 gene in human ovarian cancer cells disrupts F-actin stress fiber and leads to apoptosis. Oncogene 20:6700-6, 2001. e-Pub 2001.
260. Xu F, Xia W, Zhao Z, Peng P, Luo RZ, Dai J, Long Y, Zhao L, Le W, Liu J, Parlow AF, Hung MC, Jr BR, Yu Y. The human ARHI tumor suppressor gene inhibits growth and lactation in transgenic mice. Cancer Res 60:4913-20, 2000. e-Pub 2000. PMID: 10987306.
261. Liu J, Prolla G, Rostagno A, Chiarle R, Feiner H, and Inghirami G. The alternative translational initiation from a downstream in-frame AUG of BRCA1 results in a novel isoform of BRCA1 protein ΔBRCA1 (17aa). Oncogene 19:2767-73, 2000. e-Pub 2000.
262. Liu W, Ittmann M, Liu J, Schoentag R, Tierno P, Greco MA, Sidhu G, Nierodzik M, and Wieczorek R. Human parvovirus B19 bone marrow from adults with AIDS: A comparative study using in situ hybridization and immunohistochemistry. Human Pathol 28:760-6, 1997. e-Pub 1997. PMID: 9224741.
263. Liu J, Suhl M, Reubin R, Zagzag D, and Greco MA. Diffuse mineralization in a patient with acquired immunodeficiency syndrome: a case report. Ped Pathol and Lab Med 17:591-8, 1997. e-Pub 1997.
264. Patel YM, Yun JS, Liu J, McGrane MM, and Hanson RW. An analysis of regulatory elements in the phosphoenolpyruvate carboxykinase (GTP) gene which are responsible for its tissue specific expression and metabolic control in transgenic mice. J Biol Chem 269:5619-28, 1994. e-Pub 1994. PMID: 8119898.
265. Liu J, Woffendin C, Yang ZY, and Nabel GJ. Regulated expression of a dominant negative form of Rev improves resistance to HIV infection in T cells. Gene Ther 1:32-7, 1994. e-Pub 1994. PMID: 7584057.
266. Gurney AL, Park EA, Liu J, Giralt M, McGrane MM, Patel YM, Savon S, and Hanson RW. Metabolic regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression. J Nutr 124(8):1533S-9S, 1994. e-Pub 1994.
267. Gurney AL, Park EL, Giralt M, Liu J, and Hanson RW. Opposing action of Fos and Jun oncoproteins on the transcription of phosphoenolpyruvate carboxykinase (GTP) gene: Dominant negative effect of Fos. J Biol Chem 267:18133-9, 1992. e-Pub 1992. PMID: 1325459.
268. Kalvakolanu DR, Liu J, Hanson RW, Harter ML, and Sen GC. Adenovirus E1A represses the cyclic AMP induced transcription of the gene for phosphoenolpyruvate carboxykinase (GTP) in hepatoma cells. J Biol Chem 267:2530-6, 1992. e-Pub 1992. PMID: 1310318.
269. Liu J, Perkins ND, Schmid RM, and Nabel GJ. Specific NF-kappa B subunits act in concert with Tat to stimulate human immunodeficiency virus type 1 transcription. J Virol 66:3883-7, 1992. e-Pub 1992.
270. Brady P, Park EA, Liu J, Hanson RW, and Brady LJ. Isolation and characterization of the promoter for the gene coding for the 68 κDA carmitine palmitoyltransferase from the rat. Biochem J 286:779-83, 1992. e-Pub 1992.
271. Malim MM, Freimuch WW, Liu J, Boyle TJ, Lyerly HK, Cullen BR, and Nabel GJ. Transdominant Rev protein inhibits HIV replication without affecting T cell function. J Exp Med 176:1197-201, 1992. e-Pub 1992.
272. Giralt M, Park EA, Gurney AL, Liu J, Hakimi P, Hanson RW. Identification of thyroid responsive elements in the phosphoenolpyruvate carboxykinase (GTP) gene: evidence of synergistic interaction with cAMP responsive elements. FASEB Meeting 266, 1991. e-Pub 1991.
273. Brown JW, Haas ES, James BD, Hunt DA, Liu J, and Pace NR. Phylogenetic analysis and evolution of RNase P RNA in proteobacteria. J Bacteriol 173:3855-63, 1991. e-Pub 1991.
274. Liu J, Park EA, Gurney AL, Roesler WJ, and Hanson RW. AMP induction of phosphoenolpyruvate carboxykinase (GTP) gene transcription is mediated through multiple promoter elements. J Biol Chem 266:19095-102, 1991. e-Pub 1991.
275. Liu J, Hanson RW. Regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression. Mol Cell Biochem 104:89-100, 1991. e-Pub 1991.
276. Liu JS, Roesler WJ, Hanson RW. An efficient method for introducing block mutations into specific regions of a gene. Biotechniques 9(6):738-42, 1990. e-Pub 1990. PMID: 2176793.
277. Klemm DJ, Roesler WJ, Liu J, Park EA, Hanson RW. In vitro analysis of promoter elements regulating transcription of the phosphoenolpyruvate carboxykinase (GTP) Gene. Mol Cell Biol 10(2):480-4, 1990. e-Pub 1990. PMID: 2300049.
278. Park EA, Roesler WJ, Liu J, Klemm DJ, Gurney AL, Thacher JD, Shuman J, Friedman A, and Hanson RW. The role of CCAAT/Enhancer binding protein in the transcriptional regulation of the gene for phosphoenolpyruvate carboxykinase (GTP). Mol Cell Biol 10(12):6264-72, 1990. e-Pub 1990.
279. Roesler WJ, Park EA, Klemm DJ, Liu J, Gurney AL, Vandenbark GR, and Hanson RW. Modulation of hormonal response elements by promoter environment. Trends in Endocrinol & Metabol Sept./Oct:347-51, 1990. e-Pub 1990.
280. James BD, Olson G, Liu J, Pace NR. The secondary structure of ribonuclease P RNA, the catalytic element of a ribonucleoprotein enzyme. Cell 52(1):19-26, 1988. e-Pub 1988. PMID: 2449969.

Review Articles

1. Wu TP, Li X, Ba S, Jones P, Hansel DE, Liu J. Meeting report: 1st international conference on polyploid giant cancer cells-biology, clinical applications, and the birth of a new field in cancer research. Cancer Lett 612, 2025. e-Pub 2025. PMID: 39793754.
2. Bayraktar E, Chen S, Corvigno S, Liu J, Sood AK. Ovarian cancer metastasis: Looking beyond the surface. Cancer Cell 42(10):1631-1636, 2024. e-Pub 2024. PMID: 39270645.
3. Liu J, Niu N, Li X, Zhang X, Sood AK. The life cycle of polyploid giant cancer cells and dormancy in cancer: Opportunities for novel therapeutic interventions. Semin Cancer Biol 81:132-144, 2021. e-Pub 2021. PMID: 34670140.
4. Liu J. Giant cells: Linking McClintock's heredity to early embryogenesis and tumor origin throughout millennia of evolution on Earth. Semin Cancer Biol (81):176-192, 2021. e-Pub 2021. PMID: 34116161.
5. Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M, Campbell K, Cano A, Casanova J, Christofori G, Dedhar S, Derynck R, Ford HL, Fuxe J, García de Herreros A, Goodall GJ, Hadjantonakis AK, Huang RJY, Kalcheim C, Kalluri R, Kang Y, Khew-Goodall Y, Levine H, Liu J, Longmore GD, Mani SA, Massagué J, Mayor R, McClay D, Mostov KE, Newgreen DF, Nieto MA, Puisieux A, Runyan R, Savagner P, Stanger B, Stemmler MP, Takahashi Y, Takeichi M, Theveneau E, Thiery JP, Thompson EW, Weinberg RA, Williams ED, Xing J, Zhou BP, Sheng G, Association EMT. Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 21(6):341-352, 2020. e-Pub 2020. PMID: 32300252.
6. Liu J. The "life code": A theory that unifies the human life cycle and the origin of human tumors. Semin Cancer Biol 60:380-397, 2019. e-Pub 2019. PMID: 31521747.
7. Chen J, Niu N, Zhang J, Qi L, Shen W, Donkena KV, Feng Z, Liu J. Polyploid Giant Cancer Cells (PGCCs): The Evil Roots of Cancer. Curr Cancer Drug Targets 19(5):360-367, 2019. e-Pub 2019. PMID: 29968537.
8. Liu J. The dualistic origin of human tumors. Semin Cancer Biol 53:1-16, 2018. e-Pub 2018. PMID: 30040989.
9. Guo F, Wang YM, Liu J, Mok S, Xue F, Zhang W. CXCL12/CXCR4: A symbolic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks. Oncogene 35(7):816-26, 2016. e-Pub 2016. PMID: 25961926.
10. W Chen HH, Chen W, Liang Z, Tsai W, Long Y, Aiba I, Fu S, Broaddus R, Liu J, Feun LG, Savaraj N, Kuo MT. Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy. Expert Opin Ther Targets 19(10):1307-17, 2015. e-Pub 2015. PMID: 26004625.
11. Li HX, Lu ZH, Shen K, Cheng WJ, Malpica A, Zhang J, Wei JJ, Zhang ZH, Liu J. Advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis. Int J Clin Exp Pathol 7(3):848-857, 2014. e-Pub 2014. PMID: 24696706.
12. Chen X, Zhang J, Zhang ZH, Li HX, Cheng WJ, Liu J. Cancer stem cells, epithelial-mesenchymal transition, drug resistance in high grade serous carcinoma. Hum Pathol 44(11):2373-84, 2013. e-Pub 2013. PMID: 23850493.
13. Zhang J, Liu J. Tumor stroma as targets for cancer therapy. Pharmacol Ther 137(2):200-15, 2012. e-Pub 2012. PMID: 23064233.
14. Schauer IG, Sood AK, Mok S, Liu J. Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia 13(5):393-405, 2011. e-Pub 2011. PMID: 21532880.
15. Shen Y, Yang F, Liu J. Updates on histologic grading and pathogenesis of ovarian serous carcinomas. Chinese Journal of Pathology 40(8):507-510, 2011. e-Pub 2011.
16. Zhang J, Guo X, Liu J. Histologic Grading of Serous Carcinoma and Clinical Implication (Chinese). Chinese Journal of Obstetrics and Gynecology 18(10):1353-56, 2011. e-Pub 2011.
17. Rosen DG, Zhang ZH, Shan W, Liu J. The morphologic and molecular basis of ovarian serous carcinoma. J Biomedical Res 24(4):257-263, 2010. e-Pub 2010.
18. Shan W, Liu J. Inflammation: a hidden path to breaking the spell of ovarian cancer. Cell Cycle 8(19):3107-11, 2009. e-Pub 2009. PMID: 19738436.
19. Shan W, Liu J. Epithelial ovarian cancer: Focus on Genetics and Animal Models. Cell Cycle 8(4):731-5, 2009. e-Pub 2009. PMID: 19221485.
20. Wang Y, Ji P, Liu J, Broaddus RR, Xue F, Zhang W. Centrosome-associated regulators of the G2/M checkpoint as targets for cancer therapy. Mol Cancer 8(1):8, 2009. e-Pub 2009. PMID: 19216791.
21. Rosen DG, Yang G, Liu G, Mercado-Uribe I, Chang B, Xiao XS, Zheng J, Xue FX, Liu J. Ovarian Cancer: Pathology, Biology, and Disease Models. Front Biosci 14:2089-102, 2009. e-Pub 2009. PMID: 19273186.
22. Shan W, Yang G, Liu J. The inflammatory network: bridging senescent stroma and epithelial tumorigenesis. Front Biosci 14(11):4044-57, 2009. e-Pub 2009. PMID: 19273333.
23. Hennessy BT, Murph M, Nanjundan M, Carey M, Auersperg N, Almeida J, Coombes KR, Liu J, Lu Y, Gray JW, Mills GB. Ovarian cancer: linking genomics to new target discovery and molecular markers--the way ahead. Adv Exp Med Biol 617:23-40, 2008. e-Pub 2008. PMID: 18497028.
24. Wang X, Freedman RS, Liu J, Kavanagh JJ. Immunobiology of gestational trophoblastic disease. Int J Gyn Cancer 16(4):1500-15, 2006. e-Pub 2006. PMID: 16884358.
25. Bast RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K. New tumor markers, CA125 and beyond. Int J Gynecol Cancer 15(3):274-81, 2005. e-Pub 2005. PMID: 16343244.
26. Valbuena J, Levenback C, Mansfield P, Liu J. Angiosarcoma of spleen clinically presenting as metastatic ovarian cancer. A case report and review of literature. Ann Diag Pathol 9(5):289-292, 2005. e-Pub 2005. PMID: 16198958.
27. Naora H, Cheng WJ, Liu J, Yoshida H, Rosen DG. Hox genes offer clues to type and grade of ovarian cancer. Cancer Biology and Theraphy 4(5), 2005. e-Pub 2005.
28. Rosen DG, Liu J. Prognostic markers in epithelial ovarian cancer. Tumors:14-22, 2005. e-Pub 2005.
29. Baykal A, Rosen D, Zhou C, Liu J, Sahin AA. Telomerase in breast cancer: a critical evaluation. Adv Anat Pathol 11(5):262-8, 2004. e-Pub 2004. PMID: 15322492.
30. Goto M, Tanyi J, Lahad J, Liu S, Yu S, Lapushin R, Hasegawa Y, Lu Y, Trost R, Bevers T, Jonasch E, Aldape K, Liu J, James RA, Ferguson CG, Xu Y, Prestwich GD, Mills GB. Lysophosphatidic acid production and action: Validated targets in cancer?. J Cell Biochem 92(6):1115-40, 2004. e-Pub 2004. PMID: 15258897.
31. Freedman RS, Deavers M, Liu J, Wang E. Peritoneal inflammation - A microenvironment for Epithelial Ovarian Cancer (EOC). J Transl Med 2(1):23, 2004. e-Pub 2004. PMID: 15219235.
32. Ramirez PT, Wolf JK, Malpica A, Deavers MT, Liu J, Broaddus R. Wolffian duct tumors: Case reports and review of the literature. Gynecol Oncol 86(2):225-30, 2002. e-Pub 2002. PMID: 12144833.
33. Bast RC, Jr, Urban N, Shridhar V, Smith D, Zhang Z, Skates S, Lu K, Liu J, Fishman D, Mills G. Early detection of ovarian cancer: promise and reality. Cancer Treat Res 107:61-97, 2002. e-Pub 2002. PMID: 11775462.

Other Articles

1. Wan, L, Xu, K, Wei, Y, Zhang, J, Han, T, Fry, C, Zhang, Z, Wang, YV, Huang, L, Yuan, M, Xia, W, Chang, W, Huang, WC, Liu, CL, Chang, YC, Liu, J, Wu, Y, Jin, VX, Dai, X, Guo, J, Liu, J, Jiang, S, Li, J, Asara, JM, Brown, M, Hung, M, Wei, W Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function (Molecular Cell (2018) 69(2) (279–291.e5), (S1097276517309814), (10.1016/j.molcel.2017.12.024)). Molecular cell 85(15):3002, 2025. PMID: 40706598.
2. Liu J, Li X Provided an image of polyploid giant cancer in a Feature Article by Elizabeth Pennisi. Science 381(6660), 2023.
3. Liu J Comment cited in an Editorial Article by Lesie Mitch. Science, 2023.
4. Lu W, Hu Y, Chen G, Chen Z, Zhang H, Wang F, Feng L, Pelicano H, Wang H, Keating MJ, Liu J, McKeehan W, Wang H Correction: Novel role of NOX in supporting aerobic glycolysis in cancer cells with mitochondrial dysfunction and as a potential target for cancer therapy. PLoS Boi 15(12):e1002616, 2017. PMID: 29227990.
5. Wang Y, Hu L, Ji P, Teng F, Tian W, Liu Y, Cogdell D, Liu J, Sood AK, Broaddus R, Xue F, Zhang W Erratum to: MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis. J Hematol Oncol 10(1):163, 2017. PMID: 28985752.
6. Pan Y, Robertson G, Pedersen L, Lim E, Hernandez-Herrera A, Rowat AC, Patil SL, Chan CK, Wen Y, Zhang X, Basu-Roy U, Mansukhani A, Chu A, Sipahimalani P, Bowlby R, Brooks D, Thiessen N, Coarfa C, Ma Y, Moore RA, Schein JE, Mungall AJ, Liu J, Pecot CV, Sood AK, Jones SJ, Marra MA, Gunaratne PH Correction: miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. Oncotarget 8(10):17406, 2017. PMID: 28403581.
7. Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, Bondy M, Liu J, Hunt KK, Keyomarsi K Erratum to: Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res 17(1):87, 2015. PMID: 26108797.

Editorials

1. Liu J, Erenpreisa J, Sikora E. Special Issue on Polyploidy, Senescence, Evolution, and Cancer. Polyploid giant cancer cells: An emerging new field of cancer biology. Semin Cancer Biol 81:1-4, 2021. PMID: 34695579.
2. Liu J. The Origin of Tumors: Time for New Paradigm? The 150 most important questions in cancer research and clinical oncology series: Question #91 in questions. Cancer Communications 38(69):94-101, 2018. PMID: 29357949.

Abstracts

1. Nie H, Zhou W, Cheng K, Guo D, Liao L, Zhang X, Wang C, Zielinski RJ, Gavade JN, Sriramkumar S, Fang Y, Wu S, Tang H, Kossenkov AV, Qi Y, Liu J, Le K, Gruber D, Soth MJ, Post MD, Sood AK, Flückiger-Mangual S, Yap TA, Bitler BG, Zhang R. Low physiological pH drives P300-mediated acetylation of PARP1 and promotes PARP inhibitor resistance. AACR Annual Meeting, 2026.
2. Liu J. What is Cancer: a Holistic View through the Lens of Super-Giant Cells from a Pathologist. Third International Cancer Science Congress 2025, 2025. e-Pub 2025.
3. Liu J. “Life Code”: Toward a Unified Understanding of Embryogenesis and Tumorigenesis on the Organismal Level. 9th AI and Digital Pathology Congress: Asia 2025, 2025. e-Pub 2025.
4. Liu J. Giant cell-mediated whole genome reprograming: Toward a unified understanding embryogenesis and tumorigenesis. Cold Spring Harbor Meeting:p68, 2025. e-Pub 2025.
5. Hameed N, Ramalingam P, Liu J, Malpica A, Euscher E. Pilomatrix-Like High Grade Endometrioid Carcinoma: A Clinicopathologic Study of 14 cases. Lab Invest 105(3):47-48 #988, 2025. e-Pub 2025.
6. Taha H, Liu J, Euscher E, Ramalingam P. SOX17 and β-Catenin Expression in Dedifferentiated/Undifferentiated Endometrial Carcinomas. Lab Invest 105(3):138 #1085, 2025. e-Pub 2025.
7. Sun H, Zheng L, Huang X, Han C, Liu J, Wu Y, Ding Q. A Comparison of Three TRPS1 Antibodies in Detecting TRPS1 Expression in Breast Carcinoma and Ovarian Serous Carcinoma. Lab Invest 105(3):14-15 #748, 2025. e-Pub 2025.
8. Liu J. Giant Cells: A new paradigm to understand tumor origins and decode their complexity at the organismal level. Meeting of the International Ovarian Cancer Research Consortium and The International Society of Precision Cancer Medicine. University of Oklahoma, 2023. e-Pub 2023.
9. Liu J. Giant Cells: A paradigm to decoding cancer complexity and integrates science. American Association of Cancer Research Annual Meeting 83(7):#145, 2023. e-Pub 2023.
10. Li X, Zhong Y, Zhang X, Sood A, Liu J. Spatial-Temporal View of Malignant histogenesis and macroevolution via formation of polyploid giant cancer cells. Cancer Res 83(7):#108, 2023. e-Pub 2023.
11. Wang GL, Liu Y, Ramalingam R, Malpica A, Euscher ED, Lawson BC, Hameed N, Sood AK, Rafei H, Basar R, Rezvani K, Jazaeri AA, Liu J. TROP2 Expression is A Favorable Prognostic Marker in Patients with Advanced High Grade Ovarian Carcinoma. United States and Canadian Academy Annual Pathology Meeting 103(3 Supplement):S998-99 #985, 2023. e-Pub 2023.
12. Vo DM, Liu Y, Sood AK, Rezvani K, Jazaeri AA, Liu J. Over-Expression Of EGFR Is Associated With Poor Prognosis In High Grade Ovarian Carcinoma. Lab Invest 103(3):S996-97 #983, 2023. e-Pub 2023.
13. Zhang X, Yao J, Li X, Niu N, Liu Y, Sood AK, Liu J. Targeting polyploid giant cancer cells to overcome resistance to PARP inhibitors in ovarian cancer. Cancer Res 82(12_Supplement):#3249, 2022. e-Pub 2022.
14. Zhang, X, Niu N, Li X, Sood, A, Liu J. Specific Expression of SOX17 in Tumors of Mullerian Origin. Lab Invest 35(2):858 #979, 2022. e-Pub 2022.
15. Niu N, Li X, Yao J, Sood A, Liu J. Polyploid giant cancer cells lead to evolution of drug resistance in high-grade ovarian cancer. Cancer Res 80(11_Supplement):A17, 2020. e-Pub 2020.
16. Niu N, Zhong YP, Jazari, Sood A, A, Liu J. Expression of B7-H4 and IDO1 is associated with drug response and prognosis of ovarian high grade serious carcinoma. United States and Canadian Academy Annual Meeting 100(1):1114, 2020. e-Pub 2020.
17. Zhong YP, Lawson B, Malpica A, Ramalingam R, Euscher E, Fleming N, Sood, A, Liu J. Histologic features associated with chemotherapy response. United States and Canadian Academy Annual Pathology Meeting 32(Suppl 2), 2019. e-Pub 2019.
18. Liang L, Jiang Y, J-S C, Niu N, Ning J, Liu J. B7-H4 Expression in Ovarian Serous Carcinoma: A study of 306 tissue samples. United States and Canadian Academy Annual Pathology Meeting 57:1-6, 2016. e-Pub 2016.
19. Liang L, Olar A, Jiang Y, Niu N, Yemelyanova A, Fuller G, Liu J. Primary Glial and Neuronal Tumors of the Ovary or Peritoneum: A Clinicopathologic Study of 11 Cases. United States and Canadian Academy Annual Pathology Meeting 29(2):295A #1172, 2016. e-Pub 2016.
20. Liu J. Giant Cancer Stem Cells of High Grade Serous Carcinoma. American Cancer Association of Cancer Research, Ovarian Cancer Conference 22(2):#B49, 2016. e-Pub 2016.
21. Liang L, Zhang YF, Malpica M, Ramalingam P, Euscher E, Liu J. Sox2 is Expressed in Gliomatosis Peritonei: A Clinicopathologic and Immunohistochemical Study of 21 Cases. Modern Pathol, 2015. e-Pub 2015.
22. Liu J, Mercado-Uribe I, Na N, Kuang K, Sun BC, Zhang S. Re-thinking about the concept of cancer stem cells: Polyploid giant cells as mother cancer stem cells. Proc Am Assoc Cancer Res (AACR) 74(19_Supplement):#1917, 2014. e-Pub 2014.
23. Huang J, Zhang J, Shan WW, Mercado-Uribe I, Liu J. VCAM1 expression correlated with tumorigenesis and poor prognosis in high grade serous ovarian cancer. United States and Canadian Academy Annual Pathology Meeting, 2013. e-Pub 2013.
24. Zhang J, Chang DY, Mercado-Uribe I, Liu J. Sex-determining region Y-box 2 expression predicts poor prognosis in human ovarian carcinoma. United States and Canadian Academy Annual Pathology Meeting, Vancouver, 2012. e-Pub 2012.
25. Mercado-Uribe I, Shan W, Liu J. Induction of Mucinous Adenocarcinoma through Genetic Modification and Peritoneal Microenvironment of Fallopian Tubal Epithelial Cells. Proc Am Assoc Res (AACR):#1602, 2011. e-Pub 2011.
26. Yang F, Guo X, Yang G, Rosen DG, Liu J. AURKA and BRCA2 expression highly correlate with prognosis of endometrioid ovarian carcinoma. United States and Canadian Academy Annual Pathology Meeting, 2011. e-Pub 2011.
27. Shan W, Yang G, Mercado-Uribe I, Liu J. The Pro-inflammatory Secretory Phenotype and Selection of Stem-like Cells in RAS-transformed Ovarian Epithelial Cells. Proc Am Assoc Cancer Res (AACR) 70(8_Supplement):#4230, 2010. e-Pub 2010.
28. Zheng J, Mercado-Uribe I, Liu J, Rosen DG, Yang G, Malpica A, Naora H, Auersperg N, Mills GB. Human ovarian surface epithelial cells can give rise to papillary serous carcinoma under the influence of specific oncogenes and the microenvironment. United States and Canadian Academy Annual Pathology Meeting 89(Suppl 1):243A #1107, 2009. e-Pub 2009.
29. Chang B, Liu GZ, Rosen DG, Wang XM, Xiao LC, Liu J. ALDH1 expression in ovarian cancers: Correlation with histologic type and clinical prognosis. United States and Canadian Academy Annual Pathology Meeting 89(Suppl 1):209A #950, 2009. e-Pub 2009.
30. Djordjevic B, Rosen DG, Liu J. Overexpression of EGFR is a Poor Prognostic Indicator in ovarian cancer. United States and Canadian Academy Annual Pathology Meeting 89(Suppl 1):212A #963, 2009. e-Pub 2009.
31. Chang B, Liu G, Yang G, Mercado-Uribe I, Huang M, Liu J. REDD1 is required for RAS-mediated transformation of human ovarian epithelial cells. Proc Am Assoc Cancer Res (AACR), 2009. e-Pub 2009.
32. Feng W, Duan X, Liu J, Xiao J, Brown RE. Morphoproteomic evidence of activated mTOR pathway in cervical carcinoma and high-grade squamous intraepithelial lesion. Lab Invest 88(930):230A, 2008. e-Pub 2008.
33. Bartholomeusz C, Rosen D, Wei C, Yamasaki F, Takahashi T, Itamochi H, Kondo S, Liu J, Ueno NT. Novel ERK regulator phosphoprotein PEA-15, which induces autophagy in human ovarian cancer cells, is associated with prolonged overall survival in women with primary epithelial ovarian cancer. Proc Am Assoc Cancer Res (AACR)(5216):#5216, 2008. e-Pub 2008.
34. Li Y, Hu Y, Liu J, and Albarracin CT. Inhibitory role of annexin A1 in breast cancer cell proliferation and tumor growth. Proc Am Assoc Cancer Res (AACR) 68(9):#896, 2008. e-Pub 2008.
35. Liu G, Yang G, Mercado-Uribe I, Huang M, Zheng J, S-H L, Liu J. Stannocalcin-1 is a Transforming Oncogene in Ovarian Cancer. Proc Am Assoc Cancer Res (AACR):#202, 2008. e-Pub 2008.
36. Yang G, Liu G, Xue F, Zheng J, Mercado-Uribe I, Rosen DG, Huang J, S-H L, Mills, GB, Liu J. CXCR2 Is Required for Human Ovarian Cancer Growth through Increased Cell-cycle Progression and Enhanced Angiogenesis. Proc Am Assoc Cancer Res (AACR) 68(9):#5250, 2008. e-Pub 2008.
37. Fang B, Guo W, Wu S, Liu J. A small compound with synthetic lethality for K-ras and PKCiota. Proc Am Assoc Cancer Res (AACR) 68(9 Supplement):#1280, 2008. e-Pub 2008.
38. Shaye AN, Rosen D, Liu J. The Use of p16ink4a, but not p14arf, p15ink4b as potential marker for breast and ovarian neoplasm. Lab Invest 88(1):54A #238A, 2008. e-Pub 2008.
39. Simon RA, Xu H, Bourne PA, Yao JL, Wei J, Liang S, Liu J, di Sant′Agnese PA, Chang L, Huang J. CD44 is a useful marker for prostatic small cell carcinoma. Lab Invest 88(1):p. 182A #831, 2008. e-Pub 2008.
40. Kubba LA, Liu J, Malpica A, Euscher E, Silva E, Deavers MT. Thyroid transcription factor 1 (TTF2) immunoreactivity in ovarian neoplasm. Modern Pathology 87(1):p204A #931, 2007. e-Pub 2007.
41. Wei K, Xia W, Zhang Z, Liu J, Albraccin C, Yu D, Mills GB, Bast RC, Jr, Hortobagyi GN, Hung MC. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast and ovarian cancer. Proc Am Assoc Cancer Res (AACR) 67(9):#1158, 2007. e-Pub 2007.
42. Hara F, Samuel S, Liu J, Rosen DG, Langley R, Naora H. A homeobox gene related to Drosophila Distal-less promotes ovarian tumorigenicity by inducing expression of vascular endothelial growth factor and fibroblast growth factor-2. Proc Am Assoc Cancer Res (AACR):#3819, 2007. e-Pub 2007.
43. Zhang ZH, Singh M, Rosen DG, Yang G, Liu J. Activation of BTAK expression in primary ovarian surface epithelial cells carrying heterozygous BRCA mutation. Proc Am Assoc Cancer Res (AACR) 67(9):#1999, 2007. e-Pub 2007.
44. Yang G, Rosen DG, Liu J. Immortalization of Li-Fraumeni Ovarian Surface Epithelial Cells by Small Interfering RNA to p53 or pRb and Expression of Catalytic Subunit of Human Telomerase. Proc Am Assoc Cancer Res (AACR) 67(9):#2815, 2007. e-Pub 2007.
45. Chakravarty D, Nair S, Balasenthil S, Liu J, Tekmal RR, Auersperg N, Burow M, Broaddus R, Vadlamudi A. PLLP1/MNAR in ovarian cancer: Implication in tumorigenesis. Proc Am Asso Cancer Res (AACR) 67(9):#4345, 2007. e-Pub 2007.
46. Rosen DG, Zhang ZH, Liu J. Analysis of morphologic parameters and expression of β-catenin in endometrioid carcinoma of ovary. Lab Invest 87(1):p213A #973, 2007. e-Pub 2007.
47. Rosen DG, Liu J. Expression of p65 subunit of NF-κB is a favorable prognostic marker in ovarian cancer. Lab Invest 87(Supplement 1):206A #942, 2007. e-Pub 2007.
48. Feng WW, Shen LL, Rosen DG, Hu X, Liu J, Hunt KK, Jr BR, Issa JP, J, Yu Y. Methylation profile of multiple tumor suppressor genes in breast cancer. Proc Am Assoc Cancer Res (AACR):p759 #3220, 2006. e-Pub 2006.
49. W-W F, R-T M, Lu Z, Liu J, Lu KH, Yu Y, Jr BR. Genetic and epigenetic regulation of two imprinted tumor suppressor genes - ARHI and PEG3 - in ovarian cancer. Proc Am Assoc Cancer Res (AACR) 66(8):p371-372 #1573, 2006. e-Pub 2006.
50. Yang G, Rosen DG, Bast RC, Mills GB, Mercado-Uribe I, Liu J. Chemokine ″growth regulated oncogene 1″ (Gro-1) mediates RAS-induced transformation of human ovarian surface epithelial cells through induction of senescence of stromal fibroblasts. Proc Am Assoc Cancer Res (AACR) 66(8):p398 #1687, 2006. e-Pub 2006.
51. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Helstrom I, Mok S, Liu J, Bast RC Jr.. Potential markers that complement expression of CA125 in epithelial ovarian cancer. 13th Annual SPORE Meeting:p.198 #207, 2005. e-Pub 2005.
52. Wen X, Liu J, Bast RC, X-F AL. Her2 signaling regulates different angiogenic factors through different pathways in breast cancer cells. Proc Am Assoc Cancer Res (AACR):#2035, 2005. e-Pub 2005.
53. Liang K, Yang G, Lu Y, Li X, Liu J, Fan Z. Role of the Cbl/CIN85 pathway in regulating cellular sensitivity to cetuximab/C225-mediated antitumor activity. Proc Am Assoc Cancer Res (AACR):#5502, 2005. e-Pub 2005.
54. Cai KQ, Yang G, Rosen DG, Mercado-Uribe I, Sen S, Liu J. STK15/BTAK is involved in early step of ovarian cancer development and its expression is required for sustained tumor growth. Proc Am Assoc Cancer Res (AACR):#127, 2005. e-Pub 2005.
55. Hu Y, Rosen DG, Yang G, Zhou Y, Liu J, Huang P. Expression of Manganese superoxide dismutase (MnSOD) in human ovarian carcinoma and its role in cancer cell proliferation. Proc Am Assoc Cancer Res (AACR):#6109, 2005. e-Pub 2005.
56. Yang G, Rosen DG, Imelda M, Zhou C, Mills GB, Bast RC, Liu J. Immortalization of human ovarian surface epithelial cells using a combination of retrovirus-mediated small interfering RNA against p53 or pRb and ectopic expression of the catalytic subunit of telomerase. Proc Am Assoc Cancer Res (AACR):#6109, 2005. e-Pub 2005.
57. Kawase K, Hu Y, Liu J, Albarracin CT. Potential role of annexin A1 (ANXA1) as a growth inhibitor in breast cancer cell lines. Proc Am Assoc of Cancer Res (AACR):#2876, 2005. e-Pub 2005.
58. Trachootham D, Pelicano H, Liu J, Huang AP. Preferential induction of apoptosis in malignant cells by β-Phenetyl isothiocyanates (PEITC): Implication of ROS stress in cancer therapeutics. Proc Am Assoc Cancer Res (AACR):#4965, 2005. e-Pub 2005.
59. Bicquart C, Kawase K, Garcia MKP, Rosen DG, Symmans WF, Liu J, Albarracin CT. Evaluation of epidermal growth factor receptor (EGFR) and lymph nodes metastases using tissue microarray. Lab Invest 85(1):27A #108, 2005. e-Pub 2005.
60. Rosen DG, Yang G, Lanza JT, Liu J. Expression of hTERT and hTR RNA correlates with poor prognosis in ovarian cancer. Lab Invest 85(1):201A #936, 2005. e-Pub 2005.
61. Cheng KW, Eder A, Nanjudan M, Liu J, Gray J, Mills GB. Genomics of ovarian cancer identify new targets and prognostic markers. 13th SPORE Investigator Workshop:p50 #32, 2005. e-Pub 2005.
62. Rosen DG, Amin HM, Bast RC, Lai R, Liu J. Clinical significance STAT3 activation in human ovarian cancer. Lab Invest 85:936A #104, 2005. e-Pub 2005.
63. Marquez R, Patterson A, Yu Y, Wang L, Rosen D, Liu J, Smith D, Hartmann L, Fishman D, Berchuck A, Whitaker R, Gershenson D, Mills GB, Bast R. Frequent dysregulation of imprinted genes in ovarian cancer. Helene Harris Memorial Trust Biannual Meeting, 2005. e-Pub 2005.
64. Yoshisa H, Cheng W, Hung J, Montell D, Geisbrecht E, Rosen DG, Liu J, Naora H. Lessons from border cell migration in the Drosophila ovary: A role for myosin VI in the migration of human ovarian cancer cells. 11th Annual SPORE meeting workshop, 2004. e-Pub 2004.
65. Yoshida H, Cheng W, Hung J, Liu J, Rosen DG, Montell D, Geisbrecht E, Noara H. Inhibiting the motor protein myosin VI impedes ovarian cancer cell migration. Proc Am Assoc Cancer Res (AACR):#4519, 2004. e-Pub 2004.
66. Nunez MI, Rosen DG, Ludes-Meyers JH, Abba MC, Kil H, Page R, Klein-Szanto A J P, Godwin AK, Liu J, Mills GB, Aldaz CM. Loss of WWOX Protein Expression in Ovarian Carcinomas Correlates with Poor Outcome and Specific Histotypes. Proc Am Assoc Cancer Res (AACR):#4429, 2004. e-Pub 2004.
67. Yang G, Cai KQ, Thompson-Lanza JA, Bast RC, Jr, Liu J. Inhibition of breast and ovarian tumor growth through multiple signaling pathways using retrovirus-mediated siRNA silencing against Her-2/neu gene expression. Proc Am Assoc Cancer Res (AACR):#1191, 2004. e-Pub 2004.
68. Boerboom D, Paquet M, Hsieh M, White LD, Liu J, Sirois J, Behringer RR, Taketo MM, Richards JS. Misregulation of β-catenin signaling plays a key role in ovarian granulosa cell tumorigenesis. XIII International Workshop on the Development and Function of the Reproductive Organs, 2004. e-Pub 2004.
69. Boerboom D, Paquet M, Hsieh M, White LD, Liu J, Sirois J, Behringer RR, Taketo MM, Richards JS. Chronic activation of the canonical Wnt signaling pathway in the ovary leads to granulosa cell hyperplasia and tumor formation. Tenth Annual Texas Forum on Female Reproduction, 2004. e-Pub 2004.
70. Wang H, Rosen DG, Wang H, Fuller G, Zhang W, Liu J. IGFBPII and IGFBP V expression and prognostic significance in epithelial ovarian cancer. Modern Pathol 17:216A #907, 2004. e-Pub 2004.
71. Rosen DG, Yang G, Malpica A, Deavers MT, Liu J. Cyclin E is an independent prognostic marker of epithelial ovarian carcinoma. Modern Pathol 17:p213A #895, 2004. e-Pub 2004.
72. Cai KQ, Albarracin C, Rosen DG, Zhong R, Zheng W, Broaddus R, Luthra, R, Liu J. Microsatellite instability and alteration of expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. Modern Pathol 17:p192A #804, 2004. e-Pub 2004.
73. Yang G, Liu J. Targeting oncogene expression using siRNAs. 8th World Congress on Advances in Oncology and 6th International Symposium on Molecular Medicine, 2003. e-Pub 2003.
74. Wang L, Liu J, Jain A, Luo RZ, Rosen DG, Lu KH, Yu Y, Bast RC Jr. Expression of the tumor suppressor gene ARHI is maintained in well differentiated ovarian cancers and is associated with increased expression of p21WAF1/CIP1. Proc Am Assoc Cancer Res (AACR) 44:p1133 #4931, 2003. e-Pub 2003.
75. Yang G, Thompson JA, Fang B, Liu J. Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumor growth in a model of human ovarian cancer. 11th Annual SPORE Investigator Meeting Workshop Abstract:p83, 2003. e-Pub 2003.
76. Liu J, Patterson A, Thompson JA, Mills GB, Bast RC Jr. Transformation targets of human ovarian surface epithelial cells by oncogenic H-rasV12 or K-rasV12 revealed by gene expression array. Proc Am Assoc Cancer Res (AACR) 44:p.270 #1182, 2003. e-Pub 2003.
77. Rosen DG, Liu J. The expression of p27 is not a prognostic marker in human endometrioid. Modern Pathol 16(1):209A #953, 2003. e-Pub 2003.
78. Albarracin C, Gibori G, Rosen DG, Cai KQ, Liu J. Prognostic significance and histotype-specific expression of annexin I in human ovarian cancers. Modern Pathol 16(1):p178A #813, 2003. e-Pub 2003.
79. Lee P, Rosen DG, Cai KQ, Gershenson DM, Silva EG, Liu J. Expression of steroid hormone receptors and prognostic significance in ovarian cancer using tissue microarray. Modern Pathol 16(1):p196A #893, 2003. e-Pub 2003.
80. Prieto VG, Diwan AH, Sadick NS, Liu J, Lee P. Expression of androgen receptor co-activator ARA70 in androgenic alopecia. Modern Pathol 16(1):p98A #437, 2003. e-Pub 2003.
81. Liu J, Zhai J, Rosen DG, Lu K, and Broaddus R. Expression of mismatch repair gene hMLH6 is histotype specific. Modern Pathol 16(1):904, 2003. e-Pub 2003.
82. Rosen DG, Liu J. The expression of p27 is not a prognostic marker in human ovarian cancer. Modern Pathol, 2003. e-Pub 2003.
83. Liu J, Lee P, Rosen DG, Thompson JA, Cai KQ, McClain D, Malpica A. Expression of androgen receptor coactivator ARA70 in ovarian cancer. Modern Pathol 16(1):199A #905, 2003. e-Pub 2003.
84. Cheng W, Liu J, Hung J, Montel D, Gershenson DM, Naora H. Myosin VI expression is associated with invasive, migratory behavior of ovarian carcinoma. Proc Am Assoc Cancer Res (AACR) 44:p.1003 #4382, 2003. e-Pub 2003.
85. Rosen DG, McClain D, Deavers MT, Silva EG, Liu J. Validation of tissue microarray in human ovarian cancer. Modern Pathol 16(1):p209A #951, 2003. e-Pub 2003.
86. Marquez R, Baggerly K, Patterson A, Frumovitz M, Atkinson EN, Liu J, Smith D, Hartmann L, Fishman D, Berchuck A, Whitaker R, Jr BR, Lu KH. Gene expression array analysis distinguishes different histotypes of epithelial ovarian cancer and suggests a distinct transcriptional program for mucinous cancers. Proc Am Assoc Cancer Res (AACR) 44:p.575 #2525, 2003. e-Pub 2003.
87. Yang G, Thompson JA, Mills GB, Bast RC, Jr, Liu J. Retention of wild-type BRCA2 allele during malignant transformation of human ovarian surface epithelial cells carrying an inherited BRCA2 germline mutation. Proc Am Assoc Cancer Res (AACR) 44:p1133 #4938, 2003. e-Pub 2003.
88. Culton LK, Deavers MT, Liu J, Silva EG, Malpica A. Presentation of endometrioid carcinoma simultaneously involving the uterus and fallopian tubes. Modern Pathol 16(1):p187 #851, 2003. e-Pub 2003.
89. Zhou C, Liu J. Promoter methylation and silencing of PTEN in ovarian cancer. Proc Am Assoc Cancer Res (AACR) 44:p225 #1114, 2003. e-Pub 2003.
90. Liu J, Zhai J, Rosen DG, Lu K, Broaddus R. The expression of mismatch repair gene hMLH6 is histotype specific. Modern Pathol 16(1):198A #904, 2003. e-Pub 2003.
91. Liu J, Thompson JA, Paterson A, Auersperg N, Hahn WC, Mills GB, RC Jr AB. Modeling human ovarian cancer through genetic modification of human ovarian surface epithelial cells. Helene Harris Memorial Trust Biannual Meeting, 2003. e-Pub 2003.
92. Lee P, Liu J, Arun B, Smith T, Sahin A. Expression of androgen receptor coactivator 70 in stage I and II invasive breast cancer. Modern Pathol 16(1):p38A #160, 2003. e-Pub 2003.
93. Lee P, Sahin A, Rosen DG, Liu J. Over-expression and amplification of HER-2/neu in human ovarian cancer. Modern Pathol 16(1):p196A #894, 2003. e-Pub 2003.
94. Lu KH, Patterson A, Atkinson EN, Baggerly K, Marquez R, Liu J, Smith D, Hartmann L, Fishman D, Berchuck A, Whitaker R, RC Jr AB. Selection of potential markers for epithelial ovarian cancer with gene expression array and recursive descent partition analysis. Proc Am Assoc Cancer Res (AACR) 44:p. 573 #2520, 2003. e-Pub 2003.
95. Liu J. Human ovarian cancer tissue microarray: A high-throughput approach to identify the novel diagnostic and prognostic markers. Ann Pathol Meet Abstr, 2002. e-Pub 2002.
96. Ma J, H-Q M, H-M H, T-X L, N-J C, H-Q M, Y-X Z, Liu J, Z-X L. The prognostic significance of paranasopharyngeal space invasion in patient with nasopharyngeal carcinoma. Am Assoc Clin Oncol Ann Meet, Orlando, FL, 2002. e-Pub 2002.
97. S-N C, Luthra R, Liu J. Bax is not the target for frameshift mutation in ovarian endometrioid carcinomas with microsatellite instability phenotype. Modern Pathol 15(1):p193A #807, 2002. e-Pub 2002.
98. Wang L, Luo RZ, Liu J, Sahin AA, McWatters A, Jr BR, Yu Y. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. Proc Am Assoc Cancer Res (AACR) 43:p43 #219, 2002. e-Pub 2002.
99. Albarracin CT, Luthra R, Thompson JA, Kao S, Huang S, Liu J. RIZ, a novel tumor suppressor, is not a target of frameshift mutations in ovarian endometrioid carcinomas with microsatellite instability. Modern Pathol 15(1):190A #796, 2002. e-Pub 2002.
100. Liu J, K-H C, Thompson JA, Zheng ZW, Gershenson DM, Broaddus R, Luthra R. Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer: Clinical significance. Modern Pathol 15(1):p202A #846, 2002. e-Pub 2002.
101. Zhou C, Liu J. Inhibition of the catalytic subunit of human telomerase expression by BRCA1 in human ovarian cancer cell lines. Proc Am Assoc Cancer Res (AACR) 43:p304 #1511, 2002. e-Pub 2002.
102. Albarracin CT, Ma J, Liu J. Loss of p27 expression predicts tumor progression in ovarian endometrioid carcinoma. Modern Pathol 15(1):p191A #797, 2002. e-Pub 2002.
103. Hu W, Verschraegen CF, Hu W, Lu K, Liu J, Yung MS, Vincent M, Kudelka AP, Freedman R, Kavanagh JJ. Differential protein profile analysis of serum from normal donor and ovarian cancer patients by proteomics. Proc Am Assoc Cancer Res 43:p37 #189, 2002. e-Pub 2002.
104. Wang L, Deavers MT, Malpica A, Silva EG, Liu J. Tissue macroarray: A simple and cost-effective method for high throughput studies. Modern Pathol 15(1):p346A #1443, 2002. e-Pub 2002.
105. Deavers MT, Malpica A, Liu J, Silva EG. Ovarian sex cord-stromal tumors: An immunohistochemical study including a comparison of calretinin with inhibin. Modern Pathol 15(1):194A #814, 2002. e-Pub 2002.
106. Wang L, Chang KH, Thompson JA, Luthra R, W-X Z, Deavers MT, Silva EG, Liu J. Genetic evidence for the multifocal origin of endometrioid carcinoma in the ovary and uterus. Modern Pathol 15(1):p213A #894, 2002. e-Pub 2002.
107. Malpica A, Deavers MT, Lu K, Liu J, Atkinson EN, Gershenson DM, Silva EG. Grading ovarian serous carcinoma using a two-tier system. Modern Pathol 15(1):202A #849, 2002. e-Pub 2002.
108. Liu J, Yang Z, Thompson JA, Auersperg N, Mills GB, Hahn WC, Jr BR. Malignant transformation of human ovarian surface epithelial cell through genetic modifications. Proc Am Assoc Cancer Res (AACR) 43:p5 #23, 2002. e-Pub 2002.
109. Albarracin CT, Luthra R, Malpica A, Silva EG, Liu J. Limited role of hMLH3 and hMLH6 in ovarian endometrioid carcinomas with microsatellite instability. Modern Pathol 15(1):p190A #795, 2002. e-Pub 2002.
110. Zhou C, Huang P, Liu J. Regulation of BRCA1 depends on p53 status following treatment of cisplatin. Era of Hope, DOD Breast Cancer Res Prog Ann Meet, 2002. e-Pub 2002.
111. Liu J, Thompson JA, Hayes K, Glassman A, Yu Y, Auersperg N, Mills GB, Hahn WC, Jr BR. A genetically defined ovarian cancer model created from human ovarian surface epithelial cells. 10th Annual SPORE Investigator Meeting p49, 2002. e-Pub 2002.
112. Liu J, Thompson JA, Wu H, X-C X, Hahn WC, Deavers MT, Malpica A, Gershenson DM, Silva EG. Expression of hTERT in normal and neoplastic ovaries. Lab Invest 81(1):p139A #192, 2001. e-Pub 2001.
113. Cui X, Li H, Liu J, Feiner H. Possible involvement of a gene on chromosome 16q24 during breast tubular carcinoma development. Proc Am Assoc Cancer Res (AACR) 42:194 #1041, 2001. e-Pub 2001.
114. Sawh RN, Malpica A, Liu J, Deavers MT, Silva EG. Benign cystic mesothelioma of the peritoneum: A Clinicopathologic study of 17 Cases with immunohistochemical analysis of estrogen and progesterone receptor status. Lab Invest 81(1):145A #846, 2001. e-Pub 2001.
115. Oldham EA, Feng L, Liu J, Keating MJ, Plukett W, Huang P. Increased free radical production in cancer cells: A biochemical basis for the selective anticancer activity of methoxyestradiol. Proc Am Assoc Cancer Res (AACR) 42:192 #1021, 2001. e-Pub 2001.
116. Deavers MT, Malpica M, Liu J, Broaddus R, Silva EG. CD10 expression in endometrial stromal and smooth muscle neoplasms. Lab Invest 81(1):135A #790, 2001. e-Pub 2001.
117. Liu J, Zhou C. Subnuclear assembly of RAD51 requires a functional BRCA1 following treatment with cisplatin but ionizing irradiation. 9th Annual SPORE Investigator Meeting p123, 2001. e-Pub 2001.
118. Liu J, Thompson JA, Smith JL, Huang P, Gershenson DM, Silva EG, Zhou C. Characterization of an ovarian cancer cell line with a BRCA1 germline mutation. Lab Invest 81(1):p139A #813, 2001. e-Pub 2001.
119. Liu J, Thompson JA, Wu H, X-C X, Hahn WC, Deavers MT, Malpica A, Gershenson DM, Silva EG. Expression of hTERT in normal and ovarian cancer cell lines and tissues. Proc Am Assoc Cancer Res (AACR) 42:404 #2176, 2001. e-Pub 2001.
120. Liu J, Zhou C. Regulation of BRCA1 by p53 in benign and cancerous ovarian epithelial cells. The 9th SCBA International Symposium Meeting, 2001. e-Pub 2001.
121. Liu J, Wieczorek R, Demopoulos R, Feiner H, Inghirami G, Suhrland M, Ostrer H, Oddoux C. High frequency of 185delAG mutation of BRCA1 gene in the male breast cancer patients. Modern Pathol 13(1):26A, 2000. e-Pub 2000.
122. Zu Y, Perle M, Kumar A, Liu J, Yan Z, Waisman J. Cytogenetic and molecular cytogenetic studies of a cardiac angiosarcoma. Lab Invest 80(3):39A #214, 2000. e-Pub 2000.
123. Liu J, Prolla P, Yee Y, Feiner H, Inghirami G. A potential human BRCA1 gene knockout. Lab Invest:p23A #114, 1998. e-Pub 1998.
124. Liu J, Yin Z, Liu W, Yee H, Wieczoreck R, Inghirami G, Feiner H. Evaluation of BRCA1 in human breast cancer. Modern Pathol:p22A #109, 1997. e-Pub 1997.
125. Liu W, Ittmann M, Liu J, Schoentag R, Tierno P, Greco A, Wieczorek R. Improvement of DNA in situ hybridization (ISH) in decalcified tissue. Modern Pathol:p183A #1074, 1997. e-Pub 1997.
126. Liu W, Liu J, Schoentag R, Tierno P, Greco A, Wieczorek R. The search for human parvovirus B19 in human immunodeficiency virus (HIV) infected bone marrow. Lab Invest 74(1):130A, 1996. e-Pub 1996.
127. Brady P, Liu J, Park EA, Hanson RW, Brady LL. Isolation and characterization of the promoter for the gene coding for carnitine palmitoyltransferase. FASEB J 5(4):817, 1992. e-Pub 1992.
128. Malim MM, Freimuch WW, Liu J, Boyle TJ, Lyerly HK, Cullen BR, Nabel GJ. Trans dominant Rev protein inhibits HIV replication without affecting T cell function. Keystone Symposium: Prevention and treatment of AIDS, 1992. e-Pub 1992.
129. Liu J, Perkins ND, Schmid RM, Nabel GJ. Specific combination of NF-κB subunit acts in concert with tat-I to stimulate the HIV enhancer. Keystone Symposium Abstract: Prevention and treatment of AIDS, 1992. e-Pub 1992.
130. Giralt M, Park EA, Liu J, Gurney AL, Hanson RW. Identification of thyroid responsive elements in the phosphoenolpyuvate carboxykinase (GTP) gene: Evidence of synergistic interaction with cAMP responsive elements. FASEB Meeting, 1991. e-Pub 1991.
131. Liu J, Roesler W, Park EA, Hanson RW. Multiple promoter elements in the promoter region of phosphoenolpyuvate carboxykinase gene can mediate the cAMP induction. The Chinese Students and Scholars Symposium Abstract in Life Science. Harvard University, 1989. e-Pub 1989.
132. Pace NR, Reich C, James BD, Waugh DS, Olson GJ, Pace B, Liu J, Aprinson EZ. Structure and Catalytic Function in Bacillus subtilis Rnase P RNA. Evolution of Catalytic Function Meeting Abstract at Cold Spring Harbor Laboratory, 1987. e-Pub 1987.
133. Pace NR, Reich C, Olson GJ, Waugh DS, James J, Liu J, Pace B, Gardiner KJ, March TL. The Bacillus subtilis RNase P RNA. RNA Processing Meeting Abstract at Cold Spring Harbor Laboratory, 1986. e-Pub 1986.
134. Zhang ZQ, Li X, Tian XX, Deng LM, Dong JT, Liu J. Senescence-associated secretory phenotype drives PGCC‘s lifecycle and blastomere-like reprogramming to promote therapeutic resistance. AACR Meeting Abstract.

Book Chapters

1. Niu N, Liu J. Generation of Polyploid Giant Cancer Cells (PGCCs) from Hey Ovarian Cancer Cells and Analysis of Embryonic Properties. In: Methods Mol Biol, 281-292, 2024.
2. Liu J. Ovarian Epithelial Carcinogenesis 2nd edition. In: Gynecologic and Obstetric Pathology, Volume 2. 1. Science Press & Springer Nature, 2023.
3. Xing D, Fischer JV, Liu J. Inherited Cancer Syndromes. In: Practical Gynecologic Pathology Frequently Asked Questions. 1. Springer Nature, 345–366, 2021.
4. Coleman R, Liu J, Matsuo K, Thaker PH, Westin SN, Sood AK. Carcinoma of the Ovaries and Fallopian Tubes. In: Abeloff's Clinical Oncology. 6. Elsevier, 1525-1543.e7, 2019.
5. Zhang J, Silva EG, Sood AK, Liu J. Ovarian Epithelial Carcinogenesis. In: Gynecologic and Obstetric Pathology. Science Press& Springer Nature, 2019.
6. Liang L, Mercado-Uribe I, Niu N, Jiang J, Cheng WJ, Zhang J, Mills GB, Scott C, Sood AK, Liu J. Patient Derived Tumor Xenograft Model. In: Patient-Derived Xenograft Models of Ovarian/Gynecologic. Science Press & Springer Nature, 2017.
7. Zhang J, Liu J. New Progress in Gynecologic Pathology. In: Chinese Obstetrics and Gynecology Textbook, 2014.
8. Shan W, Liu J. Transformation of the human ovarian surface epithelium with genetically defined elements. In: Methods Mol Biol, 377-92, 2013.
9. Chang B, Liu J. Serous Borderline Tumor. In: Chinese Gynecologic Oncology Textbook, 2011.
10. Yang W, Shi DR, Liu J. Hereditary breast and ovarian cancer. In: Current Topics in Human Genetics: Studies in Complex Diseases. World Scientific Publishing Company, 773-807, 2008.
11. Rosen DG, Yang G, Bast RC, Liu J. Use of Ras-transformed human ovarian surface epithelial cells as a model for ovarian cancer. In: Methods in Enzymology, 660-676, 2006.
12. Yu Y, r L, Lu Z, Feng WW, Badgwell D, J-P I, Rosen DG, Liu J, and Bast RC. Biochemistry and Biology of ARHI (DIRAS3), an imprinted tumor suppressor gene whose expression is lost in breast and ovarian cancer. In: Methods in Enzymology, 443-454, 2006.

Letters to the Editor

1. Liu J. The role of polyploidy in tumorigenesis: confusion versus reality. Med Oncol 40: 291, 2023.
2. Liu, J. Do cancers have their origins in embryonic development or in primitive organisms?. Med Oncol 40, 2023.

Patents

1. Oncogenic Ras Specific Cytotoxic Compounds and the Methods of Use Thereof. Patent Number: PCT/US06/61219.
2. Recombinant nucleic acids for inhibiting HIV gene expression. Patent Number: 08/073836.
3. Use of Tumor susceptibility gene 101 (TSG 101) as a prognostic and diagnostic marker. Patent Number: 7897340.